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SOMMARIO 
Gli sfingolipidi sono una classe di lipidi bioattivi, al cui centro del complicato 
pathway biosintetico si trova il ceramide: una molecola bioattiva implicata nella 
regolazione di una varietà di funzioni fisiologiche che includono l’apoptosi, l’arresto 
della crescita cellulare, la differenziazione, la senescenza, la migrazione e 
l’adesione delle cellule. Il diidroceramide è l’immediato precursore lungo la via di 
sintesi de novo del ceramide ed è stato a lungo considerato una molecola inerte e 
priva di funzione nel sistema di segnalazione intracellulare. Solo recentemente tale 
molecola è stata associata alla regolazione di processi cellulari quali l’arresto del 
ciclo cellulare e la morte cellulare programmata. D'altra parte è stata anche 
dimostrata l’attività anti-apoptotica di questa molecola. Lo scopo del mio lavoro di 
tesi è stato quello di dimostrare l’attività del diidroceramide nella regolazione di 
processi implicati nella sopravvivenza cellulare agli stress. A tal fine cellule HGC-
27 sono state trattate con resveratrolo, una molecola che stimola l’accumulo di 
diidroceramide in quanto capace di inibirne la sua desaturazione. Il resveratrolo è 
un polifenolo con note proprietà antiossidanti e antitumorali, ma è anche in grado 
di promuovere la sopravvivenza cellulare in quanto, mimando una situazione di 
ridotto apporto calorico (calorie restriction), attiva le sirtuine. Diversi studi hanno 
dimostrato che questa molecola modula la via biosintetica de novo del ceramide. 
Nel mio lavoro viene dimostrato che il trattamento con resveratrolo induce 
l’accumulo di diidroceramide tramite l’inibizione della sua desaturazione da parte 
dell’enzima DEGS-1, in modo paragonabile all’inibitore specifico XM462. Tale 
accumulo si accompagna all’attivazione dell’autofagia non associata a morte 
cellulare. Inoltre una risposta simile è attivata a seguito di diversi stimoli o 
trattamenti accomunati dalla loro capacità di indurre accumulo di diidroceramide e 
in diverse linee cellulari. L’induzione autofagica, pur non incidendo sulla vitalità, ha 
mostrato avere un effetto di rallentamento della proliferazione. Infatti abbiamo 
dimostrato che  l’accumulo di diidroceramide in cellule HGC-27 induce un arresto 
temporaneo del ciclo cellulare in fase G0/G1 che si traduce in un rallentamento 
della progressione delle fasi del ciclo. Sia l’attivazione dell’autofagia che l’arresto 
del ciclo cellulare sono temporalmente successivi alla risposta a proteine unfolded 
(UPR) attivata a seguito dello stress del reticolo endoteliale causato dall’accumulo  
di diidroceramide. Tali risultati offrono un importante contributo alla comprensione 
del ruolo metabolico dei mediatori sfingolipidici e della loro considerazione nella 
terapia antitumorale. 
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ABSTRACT 
Sphingolipids are a class of bioactive lipids. Ceramide is the hub molecule of the 
intricate sphingolipid biosynthetic pathway. It is a bioactive lipid, regulating a 
number of physiological functions such as apoptosis, cell growth arrest, 
differentiation, senescence, migration and adhesion. The dihydroceramide is the 
precursor of ceramide along the de novo biosynthetic pathway. Several groups 
considered the dihydroceramide an inactive molecule. Recent studies associated  
dihydroceramide with the induction of cellular processes such as cell cycle arrest 
and programmed cell death. On the other hand this molecule also showed anti-
apoptotic properties. The goal of my doctorate project is to demonstrate the  
dihydroceramide implication in the regulation of a pro-survival cell response to 
stress. Hence, the human gastric carcinoma HGC-27 cells were treated with 
resveratrol, a molecule that induces dihydroceramide accumulation. Resveratrol is 
a polyphenol with well known anti-oxidant and anti-tumoral properties. On the other 
hand it is a calorie restriction mimetic, thus it activates sirtuins, promoting cell 
survival. A number of studies demonstrated that resveratrol modulates the 
biosynthetic de novo pathway of ceramide. Here we demonstrated that resveratrol, 
similarly to the specific inhibitor XM462, inhibits DEGS-1 desaturase activity, 
inducing dihydroceramide accumulation. This accumulation results in autophagy 
induction without affecting cell viability. We also obtained this response treating 
different cell lines with several drugs or conditions known to induce 
dihydroceramide accumulation. Although autophagy did not affect cell viability, 
however it causes a delay in cell proliferation. In fact we demonstrated that 
dihydroceramide accumulation in HGC-27 cells induces a temporary arrest in 
G0/G1 phase resulting in the delayed cell cycle phases progression. Moreover, we 
demonstrated that both autophagy activation and cell cycle arrest are temporally 
subsequent to the unfolded protein response (UPR) which is due to the 
dihydroceramide accumulation-mediated ER stress. All these results give an 
important contribute to the understanding of the metabolic role of sphingolipid 
mediators and their targeting in the anti-tumoral therapy.
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1. BACKGROUND 
Cells are constantly subjected to environment variations that can be dangerous 
and vulnerability is high during the replicative phase of the cell cycle. Therefore 
cells evolved a tightly regulated stress survival strategy, to assure their integrity 
and viability. Altered materials degrading mechanisms, cell cycle arrest, and 
autophagy are part of this strategy. Their activation is finely orchestrated, sharing 
several upstream regulative signaling pathway as well as downstream cellular 
effects. For example nutrient starvation,  calorie restriction and low-energy status 
lead to misfolded protein accumulation into the ER  and ER stress: such conditions 
trigger the UPR (as reviewed in [1]). In parallel the same stimuli also activate 
autophagy and cell cycle arrest through the inhibition of mTOR (see review [2]). 
The calorie restriction mimetic, dietary polyphenol, resveratrol, perfectly integrates 
within the signaling pathways network that regulate cell fate decision, addressing  
cells either to cell death as well as cell survival [3]. How resveratrol regulates 
cellular processes it is still poorly understood. We previously demonstrated that 
resveratrol acts modulating biosynthetic de novo pathway of ceramide inducing 
apoptosis in several tumoral cell lines [4-6] but also autophagy cell death in 
caspase 3 deficient cells [7]. Dihydroceramide is the immediate precursor of the 
pro-apoptotic molecule ceramide. The reaction to obtain ceramide from 
dihydroceramide is catalyzed by DEGS-1. Recent studies proposed several and 
controversial bioactive properties for this molecule [8-10]. The aim of the present 
manuscript is to present all literature evidences that leaded us to formulate the 
hypothesis that dihydroceramide-dependant signaling pathway may mediate the 
pro-survival resveratrol-induced autophagy and to present and discuss our 
experimental results demonstrating that dihydroceramide is the trigger of a pro-
survival response that involves UPR autophagy and cell cycle modulation.  
1.1 Sphingolipids 
1.1.1 Structure and classification 
Sphingolipids are an important class of ubiquitarian lipids present in a variety of 
organisms including eukaryotes, prokaryotes and some enveloped viruses [11]; 
[12-15]. This complex family of compounds shares a common structural feature, a 
sphingoid base backbone 2-aminoalk-(ane or ene)-1,3 diolo with stereochemistry 
(2S,3R), which can be distinguished by the chain length (that in mammalian is 
comprised mainly of a 18-carbon alkyl chain), the number of double bonds (herein 
referring to sphinganine (Sa) the saturated form, and sphingosine (So) presenting a 
4-5 unsaturated), and the presence or the absence of hydroxyls (4-
hydroxysphingosine also referred as phytosphinosine or phytosphinganine). A fatty 
acid can be amide-linked with the sphingoid bases, it results typically from 16 to 26 
carbon atoms in length (but shorter or longer N-acylsfingoids are also present), 
mostly it is saturated (but also unsaturated e.g. nervonic acid) and in some 
particular cases it can be α-hydroxylated. For example, the major sphingolipid, 
C16-ceramide, derives from palmitoyl N-linked with sphingosine; palmitoyl N-linked 
with sphinganine is named C16-dihydroceramide; and finally palmitoyl N-linked 
with the 4-hydroxy- sphingosine or sphingane is named respectively C16-
phytoceramide or C16-dihydrophytoceramide. Each one of the above mentioned N-
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acyl-sphingoids can be metabolized in more complex sphingolipids attaching 
different head groups to the hydroxyl group on C1 of the sphingoid base. The most 
abundant sphingolipid is sphingomyelin, obtained by the linkage of phosphocholine 
to ceramide. In addition, other head groups can be attached to the dihydro-, phyto-, 
or N-acylsphingoids via phosphodiester linkages (the phosphosphingolipids), via 
glycosidic bonds (the simple and complex glycosyl- galactosyl- and lactosyl- 
sphingolipids, such as cerebrosides and gangliosides), and other groups (such as 
phosphono- and arseno-sphingolipids) [8, 16]. 
1.1.2 Sphingolipid metabolism 
The sphingolipid is a class of bioactive lipids involved in several biological 
functions. Disorders in its metabolism are associated with several pathologic 
situations such as genetic diseases [17, 18], cancer [19], cardiovascular diseases 
[20], diabetes and lipotoxicity [21], neurodegenerative diseases [22], and many 
other pathologic situations .  
The sphingolipid pathway has ceramide as hub molecule, that presents strong 
bioactive properties and it is used as backbone for the biosynthesis of other 
metabolites. Many of these metabolites are bioactive as well and take part to a 
complex and finely regulated network that involves both biosynthetic and catalytic 
reactions, organized in three major branches: the de novo pathway, characterized 
by the synthesis of ceramide from the condensation of serine with palmitoylCoA; 
the complex sphingolipids pathway, where ceramide can be metabolized in several 
complex sphingolipids and from whose hydrolysis ceramide can be obtained; and 
the salvage pathway, that involves ceramide de-acylation to sphingosine and re-
acylation to ceramide. 
1.1.2.1 The de novo pathway 
The sphingoid backbone formation takes place into the endoplasmic reticulum 
(ER), starting from the condensation of serine and fatty acyl-CoA, ending with the 
formation of ceramide as the center of sphingolipid metabolism. The de novo 
pathway is the unique metabolic entry point in the sphingolipid pathway. Hence it is 
tightly regulated by multiple control levels and it is sensible to the environmental 
stimuli which can require the production of the bioactive molecules included in this 
pathway. For example, de novo pathway is activated during heat shock response 
both in mammals and in drosophila [23]; it is also induced under hypoxic stress 
[24]; it can be induced in response to metabolic loading with either serine or 
palmitate [25]; it is activated by chemotherapeutic agents [26], oxidized LDL [27], 
cannabinoids [28] and resveratrol [4].  
1.1.2.1.1.Serine palmitoyl transferase (SPT)  
SPT is a membrane-bound heterodimer [29]. Two different genes produce the 
different subunits composing the enzyme, SPT-LCB1 and SPT-LCB2, both 
necessary for the activity. The heterodimer presents only one catalytic active site 
that catalyzes the condensation of serine with palmitoylCoA obtaining 3-
ketoshinganine. SPT activity can be positively or negatively transcriptionally 
regulated by different stimuli such as endotoxins and cytokines [30], UVB 
irradiation [31], and other agents [32]. In addiction SPT is activated in a post-
transcriptional depending manner by retinoic acid [33], 4-HPR  [34], resveratrol [4] 
etoposide [35]. The substrate, serine and palmitoyl are limiting factors for the 
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reaction and So1P appears to regulate its activity even if its action is not 
understood [36]. 
1.1.2.1.2 3-ketodihydrosphingosine reductase (3KSaR) 
This enzyme is located in the ER with the active site facing the cytosolic side. This 
ubiquitarian protein catalyzes a rapid reduction of 3-ketosphinganine in Sa [37]. 
1.1.2.1.3 (Dihydro)ceramide synthases (dh)CERS) 
(Dihydro)Ceramide synthase, first identified in yeast as lag1, is a protein family 
constituted of six enzymatic isoforms named (dihydro)ceramide synthases 
(CERS1-6) or also longevity-assurance homologues (LASS1-6). The LASSs are 
localized on the ER membrane and catalyze the acylation of sphinganine obtaining 
dihydroceramide (for review [38]). Today it is widely accepted that each CERS has 
a selected substrate specificity, using preferably a fatty acid with a specific acyl 
chain length. For example CERS1 uses as preferred substrate a C18:0 acyl chain; 
CERS2 instead preferably catalyzes the synthesis of dihydroceramide with C24:0 
and C24:1 and C26:1. Also LASS3 is specialized in the synthesis of long acyl chain 
sphingolipids, preferring C24:0, C24:1, C26:0 and C26:1. LASS4 synthesizes 
C20:0 and C22:0 whereas CERS5 and CERS6 are specialized in short chain 
dihydroceramide synthesis respectively C14:0 and C16:0. The CERSs specificity in 
ceramide species synthesis is extremely intriguing since recent studies 
demonstrate that different ceramide species mediate different responses within 
cells [39].  
1.1.2.1.4 Dihydroceramide desaturase (DEGS)  
The final step of ceramide de novo synthesis pathway is the formation of the 4,5-
trans-double bound on the sphingoid base of the dihydroceramide, leading to 
ceramide formation. This reaction is catalyzed by the Δ4-dihydroceramide 
desaturase (DEGS), an enzyme recently identified and characterized [40]. It 
belongs to the desaturase/hydroxylase family, that it is characterized by the 
presence of conserved hystidine motifs in the active site [41, 42]. Two different 
enzymatic isoforms have been identified in human, named DEGS1 and 2; DEGS1 
seems to be the most expressed isoform in human, while the second isoform, 
DEGS-2, whose enzymatic activity seems to catalyze preferably  the reaction on 
phyto- substrate, seems to be expressed preferably in skin, intestine, and kidney 
cells [43, 44]. DEGS1 is localized on the ER and, in particular, its enzymatic activity 
is oriented on the cytosolic face of ER [45]. DEGS1, like other desaturase systems, 
consists in a series of coupled reactions that transport electrons from NADPH to 
the terminal desaturase which reduces oxygen [46]. The first component of these 
electron-transport chains is the flavoproteine-cytochrome b5 reductase, which 
accepts electrons from NADPH transporting them to the cytochrome b5 heme 
group; the next reaction consists in transferring electrons from cytochrome b5 to 
the terminal desaturase, using oxygen as co-substrate [47]. For this reason, events 
that induce variations in oxygen availability, or that induce variations in the 
NADP+/NADPH+H+ ratio could modulate DEGS-1 activity. Moreover it has been 
recently found that palmitate accumulation results in an increasing of mRNA 
encoding DEGS-1, resulting in a positive feedback and in which the starting 
substrate accumulation results in the activation of the final enzyme of the metabolic 
pathway [48].  
The desaturation reaction catalyzed by DEGS-1 can be reproduced in vitro using 
either dihydroceramide and dihydrosphingomyelin as substrate [49]. However, in 
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vivo DEGS-1 preferably uses dihydroceramide as substrate, leading eventually to 
dihydroSM accumulation rather than SM.     
1.1.2.2. The sphingomyelin and complex sphingolipid breakdown pathways 
The ceramide, which is produced by de novo synthesis, is mostly used for the 
sphingomyelin and monoglycosyl- (glucosyl-, galactosyl-, lactosyl-) ceramide 
biosynthesis. The first is an important component of plasma membrane, whereas 
the latter is used as backbone for more complex sphingolipids such as 
gangliosides. Since a number of stimuli can trigger the breakdown of these 
sphingolipids, producing a great amount of ceramide, these sphingolipids are 
considered as a ceramide reservoir (for review see [50]). 
1.1.2.2.1 Sphingomyelin synthase (SMS).  
Sphingomyelin (SM) is synthesized by transferring a phosphocholine from 
phosphatidylcholine to ceramide, yielding diacylglycerol as a side product [51]. This 
reaction is catalyzed by a bi-directional lipid choline phosphotransferase, existing in 
two isoforms, SMS1 and 2, which differing for intracellular localization, since SMS-
1 is localized in the lumen of the trans Golgi [52], whereas SMS-2 resides in the 
plasma membrane [53, 54]. Directionality and activity of these enzymes mainly 
depend on the substrate availability, but additional levels of control also are known 
[55].  
1.1.2.2.2 Sphingomyelinase (SMase) 
The cells obtain the major source of ceramide backbone by the breakdown of 
complex sphingolipids and in particular by the hydrolysis of SM. This reaction is 
catalyzed by a family of enzymes, named sphingomyelinases (SMases) which 
differ, for their localization and their optimal pH: the lysosomal/acid SMase 
(aSMase), secretory/Zn2+-dependent SMase (sSMase), cytoplasmatic Mg2+-
dependent/neutral SMase (nSMase) and alkaline SMase (bSMase) [56]. The SM 
hydrolysis catalyzed by SMase is finely regulated and rapidly occurs, within 
minutes, either under different stimuli such as oxidative stress [57], or in response 
to cell treatment with TNF-α [58], antibodies directed against functional molecules 
such as Fas/APO-1 or CD28 proteins [59]. Other agonists of the SM-ceramide 
cycle include cytokines and growth factors such as interleukin 1b, nerve growth 
factor, γ-interferon, as well as stress-inducing agents such as ionizing radiation, 
hydrogen peroxide, UV light, and antileukemic agents [60]. 
1.1.2.2.3 Monoglycosyl- ceramide synthase 
An important class of bioactive molecules derived from ceramide is the 
monoglycosyl-ceramides, produced by the direct transfer of the carbohydrate 
moiety from a sugar-nucleotide to the ceramide unit. Thus, ceramide is 
glycosylated to galactosylceramide (GalCer) at the lumenal leaflet of the ER by the 
transfer of galactose from a UDP-galactose donor, reaction catalyzed by a GalCer- 
synthase [61]. Ceramide can be glycosylated (GlcCer) by a GlcCer- synthase, 
reaction which unlike glycosylation to GalCer, occurs in the cytosolic leaflet of the 
Golgi apparatus [62]. 
1.1.2.2.4 Ceramide kinase (CK)  
Ceramide can be phosphorylated by ceramide kinase (for review see [63]), a 
cytosolic enzyme inserting a phosphate group onto C1-hydroxil of Sa backbone. 
This enzyme presents wide similarity with So kinase, and it shows a higher affinity 
for ceramide with acyl chain length longer than C4 [64]. The subcellular localization 
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of this enzyme is unresolved, even if it has been suggested that it occurs to the 
plasma membrane [65, 66], Golgi apparatus [67], and the cytoplasm [66].  
1.1.2.3 The salvage pathway 
Sphingolipids pathway presents an unique exit point: the ceramide de-acylation 
followed by the irreversible degradation of the sphingoid bases. So can be 
considered the hub molecule of this catabolic branch of sphingolipids pathway: the 
salvage pathway (for review see [68]). So derives from direct ceramide de-
acylation. Alternatively So can be produced from lyso-SM and lyso-GLS, the N-
deacylated derivatives of SM and GSLs [69-71]. In turn, So can be acylated to 
ceramide, or can be phosphorylated in So1P. In addition, this pathway is implicated 
in the recycling of exogenous or short-chain ceramides metabolism [72, 73]. Since 
the similarity of So and Sa, many enzymes of this pathway are shared (and 
described) within the de novo pathway. 
1.1.2.3.1 Ceramide synthases (CERS) 
It is a family constituted of six enzymatic isoforms named (dihydro)ceramide 
synthases ([dh]CERS1-6) or longevity-assurance homologues (LASS1-6), that 
catalyze the acylation of sphingosine but also sphinganine. Biochemical and 
functional characteristics were treated above. 
1.1.2.3.2 Ceramidases (CDase) 
This class of enzyme catalyze the deacylation of ceramide and dihydroceramide in 
respectively So or Sa. Different CDases were identified and classified as acid (A), 
neutral (N) and alkaline (B), according to the optimum pH for their activity. The B-
CDase  exists in three homologue forms: B-CDase1, 2 and 3. They are localized 
into the Golgi [74] or can be secreted in the extracellular space [75]. Recently Mao 
et al demonstrate that the B-CDase2 gene expression can be modulated in cancer 
cells HeLa after treatment with the anti-tumoral drug 4-HPR [76]. Another 
extensively studied member of the CDase enzyme family is A-CDase, which is 
localized into the lysosomes [77]. It is directly associated with cancer promotion 
and resistance to chemotherapy [78]. 
1.1.2.3.3 Sphingosine Kinases (SK) 
One of the most important enzyme in the sphingolipid pathway is SK, as it forms an 
essential checkpoint that regulates levels of three bioactive lipids such as So, So1P 
and ceramide [79]. This cytoplasmic enzyme exists in two isoforms, SK1 and SK2, 
different for spatial and temporal distribution and for substrate affinity. SK1 have a 
higher affinity for So than for Sa, the opposite for SK2 that can also use phytoSo as 
substrate [79]. SK activity is finely controlled by numerous regulative levels such as 
intracellular localization by PKC that can also regulate its transcription and 
translation [80], by protein-protein interaction (e.g. TRAF2) [81], by proteolysis [82] 
and by many other mechanisms [79].  
1.1.2.3.4 So1P Phosphateses (S1PP) 
The mammalian S1PPs are a part of the type 2 lipid phosphate phosphatases that 
hydrolyze So1P to reconstitute So [83]. Human SPPase1 homologue is localized to 
the endoplasmic reticulum and shows enzymatic activity toward both So1P and 
Sa1P [84].  
1.1.2.3.5 So1P lyase (SPL)  
So1P is irreversibly degraded to ethanolamine phosphate and a long-chain 
aldehyde [85] by So1P lyase (SPL), a pyridoxal 5’-phosphate dependent enzyme, 
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highly conserved through the evolution. SPL is required for maintenance levels of 
So1P and other sphingolipids and for this reason it contributes to the normal 
cellular biology and function in many species, and its loss of function is correlated 
to intestinal carcinogenesis [86].           
1.1.3 Biological function of sphingolipid involved into the de novo 
pathway 
1.1.3.1 Ceramide 
Ceramide is the hub molecule of sphingolipid metabolism; its intracellular amount is 
finely regulated and a considerable number of diseases are correlated with the 
deregulation of its metabolism. Ceramide modulation is involved in the regulation of 
different aspects of cell biology such as inflammatory response, cell proliferation, 
cell migration, apoptosis, autophagy, senescence, and differentiation [19].  
Ceramide intracellular level is modulated in response to different stimuli, such as 
cytokines, anticancer drugs, heat stress and other stress stimuli [23], which lead to 
the activation of both the de novo and the hydrolysis of complex sphingolipid 
pathway. For example, several authors reported that treatment with TNF-α triggers 
apoptosis in different cell lines through the activation of enzymes implicated in de 
novo pathway, such as CERS 5, [87] as well as increasing the SM breakdown 
through the nSMase2 activation [58]. Ceramide accumulation regulates cell biology 
using different strategies: by lipid-protein interaction and by the biophysical 
property modification of biological membranes. Recent attracting results indicate 
that ceramide acts as a second messenger by a lipid-protein interaction. An 
excellent example is the direct ceramide interaction with phosphoprotein 
phosphathase 2A (PP2A), resulting in PP2A enzymatic activation [88, 89]. Once 
that PP2A is activated by ceramide, it  dephosphorylates either protein with pro- 
and anti-apoptotic function. PP2A activation results in the inhibition of proteins that 
show anti-apoptotic function such as the protein kinase B (PKB also a.k.a. Akt) and 
Bcl-2 [90], and on the other hand it activated pro-apoptotic proteins, such as Bax 
and Bad [91]. Another important protein that seems subjected to both direct and 
indirect ceramide-mediated PP2A activation, is the kinase suppressor of Ras [92, 
93], that would mediate the activation of the axis ERK1/ERK2. Furthermore, 
ceramide also regulates apoptosis and cell cycle arrest by the activation of a 
phosphorylative cascade that involves the direct and indirect activation of PKC 
proteins [94]. Moreover, ceramide induces apoptosis increasing the permeability of 
mitochondria membrane through the formation of channels that facilitate the 
transmigration of cytochrome C from mitochondria to the cytoplasm and thus 
activating the caspase cleavage cascade [95]. In addition, ceramide directly binds 
and activates cathepsin D [96], resulting in Bax conformational change leading to 
mitochondrial release of pro-apoptotic factors like cytochrome c and Smac [97].   
1.1.3.2 The sphinganine axis 
Sa, obtained by reduction of 3-ketoSa or by deacylation of dihydroceramide, can 
be phosphorylated in C1 by SK (see above) obtaining Sa1P. Both Sa and Sa1P 
show opposite bioactive properties. Several studies  demonstrated that the 
cytotoxic effect of the mycotoxin fumonisin B1 is mediated by the sphinganine 
accumulation. On the other hand, Sa1P shows pro-survival and anti-apoptotic 
properties, through So1P receptor 1 (S1PR1) activation with subsequent activation 
of ERK and PKB [98]. It has been recently proposed that the cytotoxic effect of 4-
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HPR, an anticancer drug, currently tested in phase I clinical trials [99], is mediated 
by the balance perturbation of pro-death/pro-survival effect of these two molecules  
[76, 100].  
1.1.3.3 Dihydroceramide  
Dihydroceramide, synthesized from sphinganine by CERSs, can be desaturated in 
ceramide or alternatively, metabolized in dihydrosphingomyelin (dhSM), 
dihydroglucosyl-, galactosyl-, ceramide (respectively dhGlcCER, dhGalCER). Since 
C2-dihydroceramide did not shows biological activity, for a long time it has been 
used as negative control for C2-ceramide studies [101]. Moreover, the classical 
TLC methods cannot distinguish saturated from unsaturated ceramide; this guided 
several groups towards wrong solutions that dihydroceramide is a biological 
inactive biochemical precursor of the bioactive lipid ceramide [101]. Thereafter, the 
introduction of more accurate methods in sphingolipid analysis, based on mass 
spectrometry, leaded to reconsider the biological properties of dihydroceramide 
starting from the observation that several molecules, thought to induce their 
biological effect through ceramide accumulation, were instead found to induce 
accumulation of their saturated form, dihydroceramide. An interesting example is 4-
HPR, whose anticancer properties were thought for a long time to be due to a large 
increase in ceramide [34, 102, 103], whereas thereafter it was found to induce 
DEGS-1 inhibition and accumulation of dihydroceramide as well as other 
precursors [8, 9, 100, 104].  
Recently, an increasing number of publications have described the 
dihydroceramide signaling activity in different, and sometime contrasting, regulative 
processes of cellular life and death. Kreveka et al., showed that the silencing of 
DEGS-1 gene induced an increase in dihydroceramides, but not ceramides, 
concomitantly to cell cycle arrest in G0/G1 phase and pRb hypophophorylation in 
human neuroblastoma cells. The effect was mediated by the activation of PP1. 4-
HPR showed a comparable anti-proliferative effect associated with DEGS-1 
inhibition in cultured cells [9]. The implication of dihydroceramide in cell cycle 
regulation was also confirmed by Cabot group that reported how the over-
expression of DEGS-1 in three different cancer cell lines resulted in an increase of 
cells in S/G2/M phase, meaning an increase of cell proliferation rate, due to the 
concomitant up-regulation of cyclin D1 through the action of NF-kB. Moreover in 
this manuscript it was also reported that esophageal carcinoma cells, Eca109 cells, 
reduce cell migration when DEGS-1 gene expression was silenced using specific 
siRNA. Furthermore in the same study, it was also reported that nude mice, in 
which Eca109 cells expressing the luciferase gene and silenced for DEGS-1were 
injected into the heart, developed tumor metastases with a markedly lower severity 
than control mice [105]. This suggests DEGS-1 as a negative prognostic marker in 
patients with esophageal carcinoma. Recently, autophagy has been suggested as 
a cellular process modulated by dihydroceramide accumulation. In fact Merrill’s 
group first proposed the association of the 4-HPR –mediated dihydroceramide 
accumulation with autophagy cell death in DU145 breast cancer cells [8]. They 
justified the different cell function observed after dihydroceramide or ceramide 
accumulation, with the higher dipole potential of dihydroceramides compared to 
ceramides. This biophysical difference could result in a decrease of the packing 
density [106] and with the lower tendency of  dihydroceramide to promote flip-flop 
[107]. Moreover, since the transporting protein CERT shows a lower affinity for 
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dihydroceramide than ceramide, dihydroceramide retains longer at the ER 
membrane than ceramide [108]. Interestingly Stiban et al proposed an anti-
apoptotic action of dihydroceramide, non based on enzymatic activity. In fact, they 
reported that pre-incubation of isolated mitochondria with dihydroceramide inhibits 
ceramide channel formation indicating that it interferes with the initiation or 
nucleation of ceramide channel rather than disassembling them. They suggested 
that dihydroceramide action is to ascribe at the perturbation of 
ceramide/dihydroceramide inside the cells [10]. 
1.2 Cell survival 
A cellular “stress” can be defined as whatever condition that perturbs the cellular 
homeostasis and that results in a cellular response. The conditions can be 
distinguished in physics, such as UV exposition, temperature and radiation; 
chemical, such as pH, ion concentration, oxygen tension, redox potentials, and 
metabolite, concentrations; biological, such as contact-dependent signals, 
hormones, cytokines, and neurotransmitters, and microbial pathogens. Eukaryotic 
cells are constantly exposed to stresses, which could potentially damage them. If 
the stimuli are above a certain threshold, they could lead cells to death. Hence, 
cells evolved several strategies to maintain their homeostasis, constituted of a 
complex network of signaling pathways that regulate cellular processes and assure 
cell survival to stress. Nevertheless, these processes are also highly integrated 
with the programmed cell death pathways to guarantee a clearance of those cells 
whose integrity is irremediably compromised. Unfolded protein response (UPR) to 
endoplasmic reticulum (ER) stress, cell cycle arrest and autophagy are three main 
actors in this integrated strategy. 
1.2.1 ER stress and UPR in cell life/death regulation 
Eukaryotic cells are provided of endoplasmic reticulum (ER) an intracellular 
organelle composed of a membranous tubular network whose integrity is essential 
for cell life. In fact ER works as an intracellular Ca2+ reservoir [109], and it is 
involved in biosynthetic processes. Neo-synthesized secretory or membrane 
proteins are folded in more complex structures by numerous chaperons proteins 
residing inside the ER lumen. Moreover, the ER membrane is the site involved in 
the de novo biosynthesis of ceramide [45], and other lipids and sterols. The correct 
protein folding is essential for cell surviving. Therefore this process is guaranteed 
by a quality control system, that recognizes misfolded proteins and addresses them 
either to a chaperones mediated refolding or to the sorting out of ER to the ER-
associated degradation (ERAD) (for review see [110]). Several physiological and 
pathological conditions such as glucose deprivation, hypoxia and oxidative stress, 
but also drugs that affect protein folding such as tunicamycin or DTT, can result in 
the accumulation of misfolded proteins which exceed ER folding capacity: a 
situation called ER stress. This condition activates a high regulated cellular 
response, defined as unfolded protein response (UPR), whose goal is to reduce 
the pressure into the ER and reestablish homeostasis by protein folding efficiency 
enhancement. Thus UPR results in up-regulation of molecular chaperones and 
protein processing enzymes; in the attenuation of global protein translation, and in 
the clearance of unfolded protein. Hence, ER stress induces UPR to promote 
survival, or only if the stimuli is too prolonged or too strong, to commit cells to 
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programmed cell death strategy [111]. UPR effectors work inducing cell cycle 
arrest, senescence, differentiation and activate autophagy. 
1.2.1.1 UPR sensor proteins 
UPR is mediated by the activation of three major trans-membrane signal 
transducers: IRE1, PERK and ATF6. In normal conditions they bound Binding 
immunoglobulin protein (BiP), which inhibits their activity [112]. The accumulation 
of unfolded protein induces a switch of BiP from the trans-membrane signal 
transducers to the unfolded protein, inducing the UPR activation.    
1.2.1.1.1 Inositol requiring 1α (IRE1α)  
IRE1α is a type-I trans-membrane receptor. In normal condition it binds BiP, 
resulting inactive. During ER stress BiP-free IRE1α homodimerizes, it induces its 
autophosphorylation and becoming active [113]. Activated IRE1α activates JNK 
transcription, a transcription factor involved in pro-death signal pathways. On the 
other hand, IRE1α expresses endoribonuclease activity, inducing the splicing of a 
mRNA encoding for the transcription factor X-box binding protein 1 (XBP-1) that 
induces the transcription of several UPR target genes, including ER chaperones 
(BiP, ERdj4, ERdj5, HEDJ, GRP58, and PDIP5), ERAD components (darlin-1, 
EDEM and HRD-1 HERP, and p58IPK), transcription factors (C/EBP homologous 
protein 10 [CHOP] and the same XBP-1 gene), and other proteins related to the 
secretory pathway [114]. XBP-1 gene expression is associated with pro-survival 
strategies, in fact it has been recently demonstrated that silencing of C/EBPβ gene, 
implicated in regulation of cell proliferation and cell survival, leads to down-
regulation of XBP-1 gene accompanied by a strong inhibition of proliferation [115]. 
Spliced XBP-1 correlates with a pro-survival ER stress response. Solid tumor cells 
are subjected to chronic hypoxia, and it results essential for cancer development to 
resist hypoxic condition. Solid tumor cells subjected to hypoxia induced XBP-1 
over-expression and activated splicing of its mRNA, resulting in cell survival. Loss 
of XBP-1 severely inhibited tumor growth due to a reduced capacity for these 
transplanted tumor cells to survive in a hypoxic microenvironment [116]. In 
addition, the knockdown of XBP-1 induced apoptosis in BaF3 cells, whereas its 
constitutive expression protected BaF3 from apoptosis during IL-3 depletion [117]. 
In addition, Gupta et al. reported that an increased production of active XBP-1 was 
necessary for heat shock protein 72 (Hsp72) to exert its pro-survival effect under 
conditions of ER stress [118]. On the contrary, it has been reported that sustained 
XBP-1 activation leads to endothelial cells apoptosis [119]. The dualism of spliced 
XBP-1 can be explained with the observation that the binding of anti- and pro-
apoptotic proteins to IRE1α controls the amplitude of its signaling and determines 
cell fate during conditions of ER stress. 
1.2.1.1.2 RNA-activated protein kinase-like ER kinase (PERK) 
PERK is a type-I trans-membrane receptor that shows high similarity with IRE1 
[120]. The disassociation of BiP from PERK induces its diimerization and its 
activation by autophosphorylation. Active PERK directly phosphorylates the 
eukaryotic initiation factor 2α (eIF2α) which, once activated, reduces the formation 
of initiation complex and the recognition of AUG initiation codons. This results in a 
general reduction in protein translation [121]. However, this condition does not 
affect ATF4 mRNA translation, a protein that strongly activates the expression of 
CHOP. The activation of eIF2α PERK-mediated seems to play an essential role in 
cell survival during UPR, since PERK mutated cells are impaired to survive under 
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ER stress [122]. In addition, it has been reported that eIF2α phosphorylation by 
PERK mediated a pro-survival response, whereas its activation by GCN2 promoted 
pro-apoptotic effect. Therefore, eIF2α phosphorylation is a key step to maintain a 
balance between the life and death of a glucose-deficient cell [123]. The 
PERK/eIF2α/ATF4 arm of the UPR is implicated in regulation of autophagy through 
the up-regulation of MAP1LC3B and ATG5 genes in solid tumor cells and results 
an important mediator of hypoxia tolerance [124]. 
1.2.1.1.3 Activating transcription factor 6 (ATF6) 
ATF6 is a type-II ER trans-membrane transcription factor. BiP-free ATF6 is 
transported to the Golgi apparatus where it is cleaved. The cleaved form of ATF-6 
shows a N-terminal site necessary for transportation inside the nucleus, where it 
activates the transcription of chaperone genes as well as the transcription of 
CHOP. ATF-6α, seems to absolve a double role in cell fate regulation, ATF6α is 
essential for CHOP expression early in UPR, whereas it is not for its late 
expression in UPR. On the other hand, ATF-6α-deficient cells are less able to 
survive to prolonged stress, due to lower chaperone expression and increased 
apoptosis [125].  
1.2.1.2 UPR effector proteins: the CHOP example  
C/EBP homologous protein 10 (CHOP)  is a transcription factor, it is part of the 
growth arrest and DNA damage genes (GADD153) family, whose transcription is 
induced by genotoxic stress and growth arrest signals. CHOP over-expression is 
downstream of either PERK, ATF-4 and ATF-6 signals and is mostly involved in 
apoptosis through the over-expression of three downstream of CHOP (DOC) 
genes. Moreover it has been reported that CHOP over-expression leads to the 
down-regulation of the anti-apoptotic Bcl-2 protein [126] and the translocation from 
cytosol to mitochondria of Bax [127]. The tight relationship between CHOP and cell 
death is also demonstrated by the observation that silencing of CHOP protects 
against apoptosis [128]. CHOP is also induce gene expression suppression of the 
anti-apoptotic p21 in a p53 independent manner [129].  
1.2.2 Cell Cycle 
Cell cycle is defined as the biochemical and morphological succession of events 
necessary to cell proliferation. It can be divided in interphase and mitosis. Cells 
spend the majority of their life within the interphase, which is organized in G1, S 
and G2 phases. During G1 phase the anabolic and catabolic processes necessary 
for cells life occur. Cells remain within this cell cycle phase for an extremely 
variable time that greatly depends by cell types. Based on the duration of this 
phase cells could be divided in actively proliferating, such as cells from 
hematopoietic tissue, non proliferating cells, that are terminally differentiated, and 
cells temporary quiescent. If the requirements of genetic and cellular integrity are 
fulfilled, cells progress to S phase, which is characterized by the replication of 
genetic material and that it is followed by G2 phase. During this cell cycle phase, 
cells set the conditions for the division in two daughter cells, event that occurs 
during mitosis, also defined M phase. Under particular stressor conditions, such as, 
nutrient starvation, cell confluence, cytostatic drugs, DNA damage, cells can 
temporary suspend their proliferation, becoming quiescent (G0 phase). Thus 
quiescence could be viewed as a form of self prevention when proliferation in not 
desirable. 
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The progression along the different phases is extremely important for 
organogenesis and for a well orchestrated tissue architecture. Therefore, the 
transition from a phase to the following is finely regulated by a cascade of events 
that initiates with the formation of heterodimeric complex composed of: cyclins, the 
regulative subunit, whose expression is cell-phase specific; cyclin-dependant 
kinases (CDKs), the catalytic subunit with kinase activity. Cyclin/CDK heterodimer 
phosphorylates downstream targets necessary for cell cycle progression. The 
progression from a phase to another is subjected and regulated by checkpoints 
that verify if the optimal conditions for cell progression exist. DNA damage, but also 
nutrient starvation hypoxic condition and other stresses can activate checkpoints 
and result in cell cycle arrest.  
Cyclins are proteins that accumulate inside the cells in a cell-phase specific 
manner, and that are quickly degraded by the ubiquitine-proteosome system once 
overcame their specific phase. Nine different cyclins, named with letters from A to I, 
were identified and schematically grouped in two major classes: G1/S phase 
cyclins, that drive the cell cycle progression from G1 to the complete genetic 
material replication are Cyclin D, E and A; cyclin B is instead involved in the 
progression through the G2 phase and mitosis.  
CDKs are a class of proteins that show kinase activity only after association with a 
cyclin. These protein transfer  a phosphate on serine or threonine activating or 
inhibiting target proteins such as Rb, E2F, B-myb, other CDK, the Cdc25A 
phosphatase, p27 [130]. To date nine CDKs were identified, whose activity is finely 
regulated by several strategies: they can be activated through the binding with the 
proper cyclin [131], they can be both inactivate or inactivated respectively by 
phosphorylative of dephosphorylative events on different aminoacids [132]; 
alternatively they can be inactivated by the binding with specific CDK inhibitor 
proteins (CKI) that work inhibiting the interaction cyclin/CDK [133].  
An essential moment for the life of a cell is the decision to progress from G1 to S 
phase, duplicating its genetic material. Proliferation signals, such as a growth 
factors, trigger a signal transduction cascade Ras-mediated, that leads to the  
expression of cyclin D [134], which plays a pivotal role in cell cycle progression. 
Cyclin D family is constituted of three closely related cyclins, D1, 2 and 3. It forms a 
holoenzyme with CDK 4 or 6 that phosphorylates and inactivates the 
retinoblastoma gene product, pRb [135]. Phosphorylated pRb is no longer able to 
bind the transcription factor E2F, who becomes free to induces the overexpression 
of enzymes and regulators essential for cell cycle progression and DNA replication 
[136]. A target gene of E2F is cyclin E, a protein that specifically binds CDK2 and 
cooperates with cyclin D for pRb phosphorylation [137]. Cyclin E/CDK2-mediated 
phosphorylation of pRb is a limiting factor for the G1-to-S phase progression [138, 
139]. One of the last events characterizing the G1-to-S cell cycle phase 
progression is the expression of cyclin A, and its interaction with CDK2, that drives 
the cell to S phase [140, 141]. Cyclin A/CDK2 complex cooperates for pRb 
phosphorylation, and in addiction collaborates with cyclin E/CDK2 to activate 
proteins that are essential for pre-replicative complex formation such as the DNA 
replication factor A (RPA) or the proliferating cell nuclear antigen (PCNA) [131]. 
Moreover both cyclin E and A/CDK2 are essential to prevent re-replication events.  
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1.2.2.1 Cell Cycle in stress response 
Under undesirable or potentially dangerous environmental conditions, such as 
limited nutrient provision and growth factor depletion, hypoxia and redox 
homeostasis unbalance, or DNA damage, cycling cells can take the decision to 
temporary arrest their proliferation, until the optimal growth conditions are re-
established. The decision to continue through the cell cycle after mitosis is taken 
during G2. During the restriction point (or R point) within the G1 phase, cells takes 
the decision whether proceeding to S phase and replicating their genomic material. 
In this sense a pivotal role is played by the CKIs, that on one hand inhibit CDKs 
activity, preventing pRb phosphorylation, and activating phosphatases (PP1 and 
PP2) that remove phosphate group and activate pRb. Two families of CKI were 
described depending on structural similarity INK4 (p16INK4A, p14ARF, p15INK4B, 
p18INK4C, p19INK4D) and CIP/KIP (p21Cip1, p27Kip1, p57Kip2). The CIP/KIP 
p21 and p27 protein play an important role preventing the CDK activation inhibitors 
[142], and their loss of expression or function has been implicated in the genesis or 
progression of many human malignancies and can mediate a drug-resistance 
phenotype. However, due to their ability to interact with cyclin D1 increasing its 
transportation into the nucleus, p21 and p27 were also associated with tumors 
promotion, indicating a paradoxical effect [143]. Their regulation is modulated by 
either gene expression regulation or post-transductional modifications or proteolytic 
degradation [144].  
Cell cycle arrest in G0/G1 phase is part of an adaptive response to stress. 
Genotoxic stress is probably the best studied inducer of checkpoint activation. 
Briefly, several condition such as UV light, radiation, ROS can induces single or 
double strand DNA damages. During G1/S checkpoint a class of proteins, RADs,  
specialized to check DNA integrity, senses DNA damages, and triggers a signal 
cascade that activates the transcription factor p53. Active nuclear p53 in turns 
transactivates pro-apoptosis, pro-autophagy  and cycle arresting genes. p21 is 
directly regulated by p53, inhibits the association of cyclin D, E and A with the 
respective CDKs. The cyclin/CDK absence causes the hypophosphorylation of pRb 
and the consequent cell cycle arrest.  
Cell cycle arrest in G0/G1 phase is also the central part of a survival strategy used 
by solid cancer cells to survive prolonged state of starvation and hypoxia. Gardner 
and coworker elegantly demonstrated that cells, growing under hypoxic condition, 
reduce their proliferative rate by regulation of p27 expression [145].  
ER stress induces cell cycle arrest in G0/G1 providing the cell an opportunity to 
restore cellular homeostasis before committing to apoptosis [146]. In particular 
PERK and GCN2 mediated eIF2α phosphorylation arrests cell cycle in G0/G1 
phase by preventing cyclin D1 expression [147].   
Autophagy and cell cycle arrest are two strategies used by cells to survive stress. 
During nutrient deprivation, condition known to activate both processes, cell cycle 
is activated as a mechanism of cellular integrity preservation whereas autophagy 
maintains viability by furnishing cells with nutrients and building blocks for 
biosynthetic processes until conditions become favorable for reentry into cell cycle. 
Since these cellular responses share that same goal, the cell survival to stress, cell 
cycle and autophagy also shared common regulative pathways, and can be 
inversely regulated by the same stimuli. In particular the regulatory mechanism of 
these processes converges on mTOR regulation, that on one hand negatively 
regulate autophagy, on the other and positively modulate cell growth and 
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proliferation. In Drosophila the lost of TOR results in a cellular phenotypes typical 
of quiescent and autophagic cells such as reduced nucleolar size and 
autophagosome formation in the larval fat body [148]. Other studies show that 
treatment with mTORC-1/2 inhibitors affected T-acute lymphoblastic leukemia (T-
ALL) cell viability by inducing cell-cycle arrest in G0/G1 phase, apoptosis and 
autophagy [149]. Moreover, Crighton et al. demonstrated that activation of p53 and 
its nuclear translocation induces the expression of the pro-autophagic protein 
DRAM [150], whereas Komata et al reported that p27 overexpression, known to 
induce quiescence, is sufficient to induce autophagy [151].  
On the other hand cell arrest was also associated with cell death [152, 153], and 
p53 activation results in the activation of cell cycle arrest before apoptosis induction 
[154].    
1.2.3 Autophagy 
Autophagy is a physiological ubiquitous degradation process in eukaryotic cells, 
conserved from yeast to human. It is defined as a process involving the 
degradative delivery of a portion of the cytoplasm to the lysosome that does not 
involve direct transport through the endocytic or vacuolar protein sorting (Vps) 
pathways (for review see [155]).  
Different types of autophagy have been described, depending on the mechanism 
that mediates the delivery of cytosolic cargo to lysosomes for degradation: 
chaperone-mediated autophagy, microautophagy and macroautophagy. 
Chaperone-mediated autophagy is the selective targeting to lysosomes of cytosolic 
proteins by their direct translocation across the lysosomal membrane into the 
lysosomal lumen (for review see [156]). Microautophagy is the direct uptake of 
soluble or particulate cellular constituents into lysosomes; it involves direct 
invagination and fission of the vacuolar/lysosomal membrane under nutrient 
deprivation. This type of autophagy is implicated in micronucleophagy in 
S.cerevisie during starvation. Macroautophagy (here referred as “autophagy”) is 
the most prevalent type of autophagy. It involves double-membrane vesicles to 
sequester portions of cytoplasm that are delivered to lysosomes for degradation. 
Autophagy is responsible of degradation of long-lived proteins and damaged 
and/or surplus intracellular organelles and structures. Depending on cargo, it is 
possible to distinguish mitophagy, as a selective removal of mitochondria (for 
review see [157]); reticulophagy, as a degradation of parts of the endoplasmic 
reticule (for review see [158]); ribophagy, as a selective degradation of ribosomes 
[159];  macro- and micropexophagy, responsible of rapid decrease of peroxisomes 
within cells (for review see [160]). Autophagy is also implicated in processes such 
as protection during infection through lysosomal degradation of invading 
pathogens, also named xenophagy (for review see [161, 162]); hormone secretion 
regulation by crinophagic process comprising fusions of secretary granules with 
lysosomes [163]. Recently it has been described a function of autophagy in 
regulating intracellular lipid stores, named macrolipophagy [164]. 
1.2.3.1 Activation of autophagy 
Under physiological conditions cells undergo autophagy to get rid of aberrant or 
long-lived proteins or to degrade damaged organelles. However, autophagy flux 
can be activated under particular conditions. Nutrient deprivation, low energy state 
and insulin activate autophagy in almost every different human cell type [164, 165] 
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recycling basic building block to support the survival and to maintain cellular 
homeostasis. The sensor of the cellular energetic state is target of rapamycin 
(TOR) protein, an evolutionarily conserved protein kinas that regulates cell growth, 
cell cycle progression, nutrient import and protein synthesis in all eukaryotic cells. 
This protein was first described in yeast and it is organized in functional complex, in 
mammals mTORC1 is formed by mLST8 and raptor [166]. Increasing aminoacids, 
insulin-mediated activation of Akt pathway and increase of ATP/AMP ratio following 
high energy status, induce the binding of Rheb and Rag GTPase with mTORC1 
and its activation [167]. When activated, mTORC1 phosphorylates a class of 
autophagy-related genes (Atg), ULK1, mAtg13 and FIP200, mammalian homolog 
of Atg1, Atg13 and Atg17 in yeast. The iperphosphorylated state of these proteins 
inhibits their interaction, thus resulting inactive. Nutrient deprivation and low energy 
state inhibit mTORC1, thus ULK1, mATG13 and FIP200 are hipophosphorylated 
and can interact. The formation of the complex ULK1/mAtg13/FIP200 results 
necessary for autophagy activation [168].  
1.2.3.1.1 Autophagosome nucleation 
The autophagosome nucleation begins with the isolation of a lipid bilayer structure, 
named phagofore. Its formation originates from a phagofore assembly site (PAS), 
localized in the peri-vaquolar region [169], PAS origin is still unknown. It Is known 
that several Atg proteins take contact with PAS to facilitate phagofore formation. 
Central role in Atg recruitment is played by Beclin1 complex. This complex is 
constituted by Beclin1 and class III phosphatidylinositol-3 kinase (class III PI3K or 
hVps34); the first one does not show any enzymatic activity but it works as an 
assembly platform; the second one is responsible of the phosphorylation of PtdIns 
to PtdIns3P, whose levels seem to be important for recruitment and assembly of 
other Atg proteins, such as Atg2 and WIPI-1, on phagofore. Regulative proteins of 
this complex, that directly binds Beclin1 are UVRAG, which increases the 
interaction of Beclin1 with Vps34 and activates autophagy, and the anti-apoptotic 
Bcl-2, that negatively regulates autophagy. The mechanism that links Baclin1 
complex to ULK1 complex is still unknown. 
1.2.3.1.2 Autophagosome elongation 
After its formation, phagofore extends its edges and wraps cytoplasmic portion 
designated to lysosomal degradation. While the cargo selection in unknown, the 
elongation process is well understood [170]. Elongation depends on two ubiquitin-
like protein: Atg12 and light chain 3 protein (LC3).  Atg12 interacts  with Atg5, in a 
Atg7and Atg10, and it results important for LC3 conjugation reaction. 
Autophagosome elongation is tightly dependent on LC3. LC3 was identified 
originally as a protein co-purified with microtubule-associated proteins (MAPs) 
[171]. This protein, synthesized as a Pro-LC3, is cleaved by proteolysis from Atg4 
[172] that exposes the carboxyl terminal Gly, obtaining LC3-I. LC3-I is divided into 
N- and C-terminal subdomains. The N-terminal subdomain of LC3 is essential for 
its binding of tubulin and microtubules, the C-terminal is conjugated with 
phosphatidylethanolamine (PE). This reaction is depending on Atg7 (an E1-like 
enzyme) and Atg3 (an E2-like enzyme) [173]. The PE-conjugated form of LC3 
(LC3-II), driven by Atg12/Atg5 complex, is incorporated both on the internal and 
external face of the autophagosome. LC3 seems to be directly involved in the 
elongation process as well as in the autophagosome closure [174]. Before the 
autophagosome completion, all the Atg proteins are recycled. Atg-4 delipidates the 
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portion of LC3-II that is present on the external face of the autophagosome. Only 
the LC3-II present on the internal layer remains associated with the 
autophagosome.  
1.2.3.1.3 Maturation and degradation of autophagosome.  
After formation, autophagosome delivers its cargo to lysosome for degradation. 
Autophagosome can directly fuse with the lysosome (autolysosome) or merge with 
endosome (anphisome) with a subsequent fusion with lysosome. The fusion of 
autophagosome with endosome  is under control of proteins involved in controlling 
membrane fusion in the intracellular transport such as Rab GTPase, SNARE and 
ESCRT proteins [175, 176]). Successively lysosomal transmembrane proteins, 
such as lysosomal-associated membrane protein 2 (LAMP-2) [177], are 
responsible of autophagosome fusion with lysosome. Finally, the autophagosomal 
content is degraded by lysosomal proteases [178]. 
1.2.3.2 Autophagy and cell fate regulation. 
Autophagy is an essential cellular strategy for cell survival. Under physiological 
conditions, autophagy occurs in cells with different magnitudes depending on 
different tissues contributing to maintain cell homeostasis through lysosomal 
clearance of damaged organelles or long-lived proteins. Autophagy is thus involved 
in cell survival by apoptosis inhibition  and cells protection from stresses [179]. 
Autophagy is mainly involved in lysosomal nutrient recycle during starvation or 
calorie restriction, providing cells with substrates for oxidation and for ATP 
synthesis in mitochondria [180]. Indeed low energy status is a condition that 
strongly triggers autophagy both in vitro and in vivo, and furnishes material for 
energy production and guarantees cell survival. New born mice rapidly activate 
autophagy in almost all the tissues of their organism to counteract the starvation 
following the birth [181]. Fasting condition before cesarean section induces 
autophagy activation in human placenta [182]. 
Autophagy is implicated in the calorie restriction- mediated anti-aging effect and in 
lifespan increase observed in several animal models. In fact, in vivo studies show 
that autophagy is activated in life-long calorie restricted mammals [183]. This effect 
is mediated by the activation of SIRT-1 protein, whose overexpression increases 
lifespan of yeast and C. elegans [184]. In fact, calorie restriction induces the 
intracellular NAD+ accumulation, which activates the  NAD+ -dependant 
deacetylase SITR-1. Activated SIRT-1 deacetylates the autophagy related proteins 
Atg5 and Atg7, resulting in an autophagy increase, as reported in human colorectal 
(HCT-116) and cervical (HeLa) cancer cell [185].  
Autophagy is not just a mechanism for nutrients recycle, rather it is a highly 
regulated strategy to adapt the cell to stresses that perturb its homeostasis. It is 
activated during oxidative stress, hypoxia and pathogen. Formation of reactive 
oxygen species (ROS) strongly induces autophagy [186]; autophagy in fact 
degrades damaged mitochondria, thus reducing ROS production and supporting 
cell survival [187]. Several evidences suggest that ROS directly sustain autophagy 
flux by oxidation of a cystein of Atg-4, resulting in its activation. Active Atg-4 
promotes LC3-I conversion and autophagosome elongation [188].  
Low level of oxygen (<1%) is known as hypoxia. Hypoxia exists not only in both 
physiologic and pathologic condition such as in placenta [182, 189], during 
embryogenesis [190], but also during ischemic events [183] or in the inner part of 
rapid growth solid cancer [191]. Cells subjected to hypoxic stress activate 
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autophagy as protective mechanism. Experimental evidences suggest that hypoxia 
activates autophagy through three strategies. The first one is correlated to ROS 
production and mitochondrial degradation [192]; the second one depends directly 
on HIF1α. HIF1α in fact upregulates BNIP3 gene expression that competes with 
Beclin-1 for Bcl-2 interaction increasing Beclin-1-free cellular level and 
autophagosome initiation [193]. Finally, hypoxia seems to induce autophagy in a 
TOR dependent fashion, by TOR inhibition and block of eukaryotic initiation factor, 
eIF4F [194].        
Accumulation of long lived or damaged proteins as well as accumulation of 
misfolded proteins inside ER (ER stress) activates autophagy. UPR is a strong 
activator of autophagy that results in an elective strategy to degrade proteins 
accumulated inside ER. Moreover, UPR-related autophagy is mainly correlated 
with a pro-survival strategy to counteract ER stress dependent cell death. 
Rheumatoid and osteoarthritis synovial fibroblasts transfected with beclin siRNA 
can not undergo autophagy and thus are more susceptible to ER stress-induced 
cell death. On the other hand, silencing CHOP gene expression increases 
autophagy and improves cell survival [195]. Several evidences suggest that all the 
three signaling branches involved in UPR can regulate autophagy. Cells that carry 
non-phosphorylable eIF2α fail to activate ER stress induced autophagy, suggesting 
an important role for PERK/eIF2α axis in autophagy activation. Cytoplasmic poly-Q 
aggregates induce accumulation of unfolded proteins and subsequent ER stress 
cell death [196]. Autophagy is protective against poly-Q72-induced ER stress cell 
death, because it can degrade poly-Q aggregate. Recently it has been 
demonstrated that poly-Q72 induces ER stress mediated activation of 
PERK/eIF2α. eIF2α selective translation of transcription factors upregulates the 
transcription of Atg-12, resulting in autophagy stimulation and the LC3-I 
conjugation with PE. In addition, the upregulation of ATF-4 and CHOP, following 
the activation of PERK/eIF2α by severe hypoxia induced ER stress, results in their 
direct binding with the promoter and following upregulation of MAP1LC3B and Atg-
5 gene [124, 197]. Despite the autophagy promoting action, PERK/eIF2α has been 
reported as a pro-survival mechanism inducer. Kim et al. have recently 
demonstrated how the autophagy PERK/eIF2α axis mediate radiosensitivity in 
caspase 3/7 deficient MCF-7 cells [198]. The control of autophagy by the UPR 
sensor IRE-1α is controversial. Ogata et al., demonstrated that IRE-1α/JNK is 
necessary for pro-survival autophagy activation in human neuroblastoma cell line 
[199]. Moreover IRE-1α and the downstream signal of XBP-1 are involved in cell 
survival. Nevertheless, XBP-1 deficiency in the nervous system protects against 
amyotrophic lateral sclerosis by increasing autophagy [200], and its accumulation 
is associated with degenerative motoneurons after severe proximal axonal lesions, 
thus showing a inhibitory action on autophagy [201]. Kroemer justifies these 
observations hypothesizing that IRE/XBP1 dependent signal has a function to 
dampen excessive autophagy triggered via the PERK/eIF2α pathway [179].  
1.2.3.3 Autophagy and cell death   
Autophagy can protect cells from cell death and can inhibit apoptosis; on the other 
hand autophagy presents a pro-death face that can work independently or in 
cooperation with apoptosis leading to cell death known as type II programmed cell 
death [202]. Indeed, autophagy and apoptosis shared several regulative elements, 
for example BNIP3, DAP kinase and ceramide activate both autophagy and 
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apoptosis [203, 204], while the anti-apoptotic Bcl-2 also inhibits autophagy [205]. 
On the contrary, a number of authors demonstrated that cells undergo autophagy 
programmed cell death when apoptosis is inhibited, thus describing the type II 
programmed cell death as a substitutive and alternative cell death process [7, 206]. 
Particularly important in autophagic/apoptotic cell death crosstalk is Beclin-1 
primarily because of its ability to directly interact with Bcl-2 (for review see [207]). 
1.2.3.4 Autophagy and sphingolipids 
Sphingolipids are intimately linked with cell fate regulation, therefore their 
implication in autophagy regulation is not surprising. The heterogeneity of the 
different sphingolipids species regarding the regulation of pro-death or pro-life 
mechanism is reflected in the ability to activate a pro-death or pro-life autophagy. 
For example ceramide was described as a pro-apoptotic sphingolipid. It coherently 
shows activation of pro-death autophagy [208]. Our group described tamoxifen as 
a drug that is able to induce ceramide mediated autophagic cell death in MCF-7 
cells [6]. Ceramide activates autophagy relieving the class I PI3K/Akt/PKB pathway 
and provoking the accumulation of the gene product Atg6/Beclin-1. Moreover 
ceramide induces upregulation of the mithocondrial bound BH3-only BNIP3 protein 
[208]. Recently Zheng et al proposed dihydroceramide as pro-death autophagy 
inductor in DU145 prostate cancer cells [8].  
Ceramide and So show a markedly anti-growth and pro apoptosis effect whereas 
So1P is associated with a pro-growth, pro-survival activity [82]. Our group 
demonstrated that SK1 overexpression and relative So1P increase induced pro-
survival autophagy in MCF-7 cells, inhibiting mTORC-1 and protecting cell from 
death during starvation [6].  
 
1.3 Resveratrol 
Resveratrol is a dietary polyphenol with extensively studied antioxidant and 
antitumoral activity [4, 209]. Resveratrol main action, in most of the cancer cell 
lines tested, is to block proliferation, arresting cell cycle at the G0/S boundaries 
with final apoptotic cell death upon prolonged treatment. One decade after the 
pioneering study of Pezzuto’s group, in which resveratrol was shown to block tumor 
initiation promotion and progression in mice [210] we are now witnessing the 
beginning of resveratrol clinical trials recruiting patients with colon cancer and 
melanoma (http://www.clinicaltrials.gov). In contrast to its cytotoxicity, resveratrol 
was also shown to activate pro survival targets such as sirtuins [211, 212]. Indeed, 
resveratrol was recently reported as a calorie restriction mimetic [213, 214].  Since 
calorie restriction was suggested to exert antiaging effects [212] and autophagy is 
part of the program activated by calorie restriction in cells [215], particular attention 
has been paid to a phyto-calorie restriction mimetic such as resveratrol and its 
apoptotic or autophagic potential. The apparent dual role of this compound may be 
reconciled taking into account that resveratrol was shown to induce autophagy in a 
variety of cell lines [7, 216, 217] and to modulate the activity of Akt and AMPK, two 
important regulators of the autophagic process, although its directs targets, 
activated pathways and outcomes are still debated  [218, 219]. By virtue of its 
autophagy promoting activity, resveratrol treatment may possibly trigger a first 
(autophagic) salvage response followed by cell death with high doses and/or 
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sustained administrations or depending on the specific cell ability to resist the 
autophagic process. 
We previously demonstrated that resveratrol induces apoptotic cell death via 
accumulation and signalling of the known pro-apoptotic sphingolipid mediator 
ceramide in breast and prostate cancer cells [4, 5]. We proved that ceramide 
increased via the de novo synthesis pathway, but not from the hydrolysis of more 
complex sphingolipids such as sphingomyelins [4]. Moreover, we showed that 
tamoxifen induced autophagy is mediated by ceramide derived from increased rate 
of the de novo synthesis and that treatment with exogenous short chain analogues 
of ceramide, known to stimulate sphingolipid synthesis de novo, triggers autophagy 
[6]. Similarly, in yeast model, it was successively reported that mTor inactivation 
induces de novo sphingolipid synthesis [220]. Recently, we reported that in 
apoptosis resistant cells by caspase 3 deficiency, resveratrol induces a caspase-
independent type II cell death by stimulating autophagy via Akt dephosphorylation 
[7]. Thus autophagy may occur in response to treatment and, depending on the 
produced mediators, it may be overcome by apoptosis through caspase activation. 
In support of this concept, we showed that sphingosine-1-phosphate, a 
sphingolipid mediator derived from ceramide catabolism with signalling roles 
opposite to ceramide, triggers a ceramide independent autophagy of survival  
[221]. 
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2. MATERIALS AND METHODS 
2.1 Reagents and Antibodies 
XM462, Jaspin B, Dideuterated-C8-dihydroceramide (d2-C8-dhCER), NBD-C6-
ceramide (NBD-CER) and NBD-C6-dihydroceramide (NBD-dhCER) were kindly 
provided by Dr. G. Fabrias. Resveratrol (Resv) was purchased from Cayman 
Chemical Company (Ann Arbor, MI, USA). 3-methiladenine (3MA), etopside (Etp), 
fenretinide (4-HPR), rapamycin, CoCl2, nocodazole (NOC), leupeptin, pepstatin A, 
SRB dye, propidium iodide, trypan blue dye, acrylamide, poliacrylamide were 
purchased from Sigma–Aldrich (St. Louis, MO  USA).  
2.2 Cell Culture 
The human gastric cancer cell line HGC- 27 was purchased from Health Protection 
Agency Culture Collections (Salisbury, UK), and maintained at 37 °C in 5% CO2 in 
MEM (Euroclone) supplemented with 10% fetal bovine serum (FBS) (Euroclone), 
1% non essential aminoacids (NEAA) (Euroclone), 1% glutamine (Euroclone) and 
100 ng/ml each of penicillin and streptomycin (P/S) (Sigma). The breast carcinoma 
MDA-MB 231 and MCF-7 were purchased from ATCC (USA) cells were cultured in 
RPMI (Euroclone) added with 10% FBS and 100 ng/ml P/S. 
2.3 Cell viability 
HGC-27 cell viability was examined by the Trypan blue dye exclusion test. Cells 
were seeded in 12-well tissue culture plates at 6 x 104 cells/well allowed to adhere 
for 24 hours. Cells were counted on hemocytometer the day of treatment (T=0) and 
16, 24, 48 or 72 hours after treatment (see figure legends for treatment conditions). 
The experiment was performed in triplicate. Cells were harvested using trypsin 
0.25%. Samples were resuspended in 1 ml of PBS solution: Tripan blue dye (1:1). 
Values, evaluated as percentage of alive versus dead cells, were reported as ratio 
over control. Statistical significance versus control values was calculate using the 
two tails T-test. 
2.4 Sulforhodamine B (SRB) assay 
HGC-27 cells were seeded in a 96-wells tissue culture plate at 1 x 103 cell/well 
allowed to adhere for 24 hours before treatment. Cells were grown in media added 
vehicle only or in presence of the drug  (see figure legends for treatment 
conditions), using five wells replicates for each treatment condition. Cell 
proliferation was analyzed 0, 2, 3 or 6 days after treatment by Sulforhodamine B 
(SRB) assay. Protein were precipitated by a 10% final concentration trichloroacetic 
acid in PBS for 1 hour and 30 min at 4°C, then stained with SRB dye, 0.4% final 
concentration in PBS/1% acetic acid  for 30 min. Finally, precipitated proteins were 
washed and solubilised in 10mM Tris buffer, pH 10.6. Absorbance, optical density 
(OD), was measured at 540 nm using a microplate reader. For each treatment 
condition, proliferation index was calculated as ratio of OD of single treated over 
OD of untreated cell obtained at T=0.  
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2.5 Western blotting 
Cell treatment and collection. Cells (2.5x105 cells/plate) were seeded in 100 mm 
petri dishes, and medium without antibiotic was replaced after 24 hours. When 
cells confluence reached about 60%, media was replaced with fresh complete 
medium containing the different drugs (see figure legend for treatment condition). 
Starvation was provoked by culturing cells in the absence of both FBS and non 
NEAA media. Real hypoxic condition was obtained by blowing into the flask a gas 
mixture containing 94% N2, 1% O2 and 5% CO2. for 30 min. The flask was sealed 
using a silicon cap and cells grew under this condition for 16 or 24 hours. Cell 
harvesting, by scraping in cold PBS on ice, was performed into a specially 
designed gas chambers in which N2 was constantly blown in, maintaining an 
atmosphere that never exceeded 1% O2. Next cells were spun at 1,200 x g for 5 
min at 4°C. An aliquot of pelletted cells was used for protein quantification [222]; 
the remaining cells were resuspended in Laemmli buffer [223], boiled for 5 min and 
stored at -20°C.  
Electrophoresis and blotting.Equal amount of proteins (10 µg) were separated by 
SDS-electrophoresis using the vertical electrophoresis apparatus Mini-Protean 3 
Cell (Bio-Rad). The acrylamide gels had a concentration depending on the protein 
target: 8% for PARP, 12% for Cyclin D1 and E and 15% for LC3 detection. After 
the separation, proteins were transferred onto nitrocellulose membranes using an 
immersion Mini Trans-Blot apparatus (Bio-Rad). After blocking unspecific binding 
sites with 5% dry milk  in PBST, the membranes were incubated overnight at 4˚C 
with primary antibodies anti-LC3 (Novus), diluted 1:1000 in PBST-3% BSA, anti-
PARP diluted 1:500 (Cell Signaling Technology Inc), anti-Cyclin D1 and anti-Cyclin 
E both diluted 1:250 (Santa Cruz Biotechnology). Anti-β-Actin 1:5000 dilution 
(Sigma) was used as house keeping gene for data normalization. Membranes were 
then incubated for 2 hours at room temperature with the appropriate HRP-
secondary  antibody (from Jackson Laboratories) diluted  1:10000 in PBST- 5% dry 
milk. Proteins were detected using chemiluminescence system LiteAbLot 
(EuroClone Life Science Division) and bands intensity quantified  by Gel Doc 2000, 
using Quantity One Software (Bio-Rad). 
2.6 LC-MS analysis 
Total sphingolipid were extracted from 1.5 x 106 treated or untreated HGC-27 cell 
pellet (see figure legend for treatment conditions). Cells were harvested by 
scraping in cold PBS on ice, collected in a 1.5 ml tube, spun at 10000 x rpm for 3 
min. Cellular pellet was  washed twice with ice cold PBS and dissolved in 100 µl 
PBS. An aliquot was used for protein quantification. Cells, added with 500 µl  
MetOH, 250 µl chloroform, 100 µl water and fortified with 10 µl of internal 
standards mix containing N dodecanoylsphingosine, N 
dodecanoylglucosylsphingosine, and N dodecanoylsphingosyl phosphorylcholine, 
0.2 nmol each. Next they were lysed by 1-2 min sonication until organic phase 
separated from acqueous phase Cell lysate was incubated overnight a 48°C then, 
once cooled down to 37°C it was added with 75 µl KOH in MetOH and sonicated 
for 1-2 min. Finally it was incubated for 2 hours at 37°C, added with 3 µl glacial 
acetic acid and dried by N2.  
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The liquid chromatography-mass spectrometer consists of a Waters Aquity UPLC 
system connected to a Waters LCT Premier orthogonal accelerated time of flight 
mass spectrometer (Waters, Millford, MA), operated in positive electrospray 
ionisation mode. Full scan spectra from 50 to 1500 Da were acquired and 
individual spectra were summed to produce data points each 0.2 seconds. Mass 
accuracy and reproducibility were maintained by using an independent reference 
spray by the LockSpray interference. The analytical column was a 100 mm×2.1 
mm i.d., 1.7  m C8 Acquity UPLC BEH (Waters). The two mobile phases were 
phase A: methanol/water/formic acid (74/25/1 v/v/v); phase B: methanol/formic acid 
(99/1 v/v), both also contained 5 mM ammonium formate. A linear gradient was 
programmed - 0.0 min: 80 % B; 3 min: 90 % B; 6 min: 90 % B; 15 min: 99 % B; 18 
min: 99 % B; 20 min: 80 % B. The flow rate was 0.3 mL min-1. The column was 
held at 30 °C. Quantification was carried out using the extracted ion chromatogram 
of each compound, using 50 mDa windows. The linear dynamic range was 
determined by injecting standard mixtures. Positive identification of compounds 
was based on the accurate mass measurement with an error <5 ppm and its LC 
retention time, compared to that of a standard (±2 %). The identification of XM462 
metabolites was performed in the same samples, using the extracted ion 
chromatogram of the expected compound, using a 50 mDa window, and were 
confirmed by checking that the accurate mass measurement had an error <5 ppm. 
2.7 Dihydroceramide desaturase activity measurements 
HGC-27 Cells (1 x 106) were homogenated by sonication (30 sec sonication 
followed by 30 sec in ice, then 5 cycle of 15 sec sonication followed by 15 sec in 
ice, and finally 30 sec sonication then in ice) in 100 µl of phosphate buffer 0.2M  pH 
7.4  (Na2PO4 0.2M, NaH2PO4 0.2M). Cell homogenates were added of vector 
(N/T), 50 µM resveratrol or 8 µM XM462 for 16 or 24 hours, then DEGS-1 
enzymatic activity was assessed incubating samples for 4 hours at 37°C in a final 
reaction volume of 300 µl of phosphate buffer added with 85 µl BSA:Substrate Mix 
35 µM (BSA 3.3mg/ml in phosphate buffer, and 35 µM of 6-[N-(7-nitro-2,1,3-
benzoxadiazol-4-yl)amino]-C6-dihydroceramide, sonicated for 3 min) final 
concentration of 10 µM, and with 30 µl 1 µmol of NADH in phosphate buffer. 
Reaction was stopped adding 700 µl MeOH, then samples were mixed by 
vortexing and incubated over night at 4°C. Samples were centrifuged at 20000 x 
rpm for 3 min and supernatant was transferred in HPLC vials. HPLC analysis were 
performed with an Alliance apparatus coupled to a fluorescence detector using a 
CROMACIL-100 reverse-phase C18 column eluted with water : acetonitrile (25:75), 
both with a 0.1 % of trifluoroacetic acid, flowing at 1 mL mL-1. A total of 100 µl each 
sample was injected. The detector was set at an excitation wavelength of 465 nm 
and measure the emission wavelength at 530 nm. Each sample was run for up to 
15 min. 
  
Materials and Methods 
 
22 
 
 
2.8 Fluorescence microscopy 
HGC-27 cells were transfected with GFP-LC3 containing vector (Addgene 
Inc.,Cambridge MA, USA) (Jackson, PLoS Biol, 2005).  Transient transfection was 
performed by using FuGENE 6 transfection reagents (Roche Diagnostic Products) 
and following the procedures recommended by the manufacturer. Briefly, cells  (0.5 
x 105 cells/well) were plated in 8-well chamber slides (IWAKI), allowed to adhere 
for 24 hours and then transfected with the plasmid containing either the GFP-LC3 
conjugate or GFP (control). 24 hours later cells were briefly examined to evaluate 
fluorescent protein expression. Then the medium was supplemented with new 
medium containing the treatment molecules (resveratrol, XM462) at the final above 
specified concentrations. Starved cells received addition of medium without FCS 
and non essential aminoacids  and were submitted to the same procedures of the 
other samples.  Fluorescence images were obtained at a magnification of 40X in 
an  inverted fluorescence microscope  provided with digital camera (Zeiss,  
Germany). 
2.9 Confocal Microscopy 
HGC-27 cells were seeded into in 8-well chamber slides (IWAKI), at final 
concentration of 3.5 x 104 cells/well, allowed to adhere for 24 hours. Cells were 
then pre-treated for 15 min with 0.5µM ER-Tracker™ Red (glibenclamide 
BODIPY® TR) (Invitrogen) dissolved in HBSS (Euroclone). After the pre-treatment 
cells were washed with HEPES, they were treated with 5µM of either NBD-C8-
ceramide or NBD-C8-dihydroceramide dissolved in NBS solution (HBSS+ FBS 
1%+NEAA 1%+ L-glutamine 1%+ HEPES 1.25M). The NBD-CER/dhCER with RE 
tracker co-localization was analyzed 6 or 16 hours after cell treatment using a 
Leica TCS SP2 confocal microscope. Images were viewed at 162x magnification. 
2.10 Cell synchronization and cell cycle analysis 
Cells HGC-27 were seeded at 2.5 x 105 cells/plate into 60 mm plates. Cells were 
allowed to adhere for 24 hours, then they were synchronized inducing cell cycle 
arrest in G2/M phase with 0.2 µM nocodazole (Sigma). After 10 hours from 
nocodazole treatment, cell were released from block by replacing media with fresh 
media added of vector (0.1% ethanol) alone (NOC) or added with XM462 or d2-C8-
dhCER (see figure legends for treatment conditions). The cells were harvested and 
fixed with ethanol immediately after media replacing (T=0) or 4, 8, 16, 24, 32, 48, 
or 72 hours after release. Briefly, cell growth media is taken apart, and cells were 
typsinized for 2 min with 0.4 ml trypsin, whose action is stopped using the same 
cell growth media. About 1x106 cells were pulled down by centrifuging 5 min. at 
1500 rpm, cell pellet was washed once with 1ml PBS ice cold and again 
centrifuged with same conditions. Cells were fixed at -20°C overnight incubation 
with a 70% ethanol in PBS+FBS solution. Fixed cells were pulled washed once 
with ice cold PBS and stained at RT 1 hour with propidium iodide (PI) in 50 µg/ml in 
1ml PBS. Stained cells were analyzed  by flow cytometry using a FACSort (Becton 
Dickinson); data analysis was performed using the software CyflogicTM (CyFlo Ltd, 
Finland) 
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2.11 Reverse transcription PCR (RT-PCR) 
Cells HGC-27 were seeded at 1.5 x 105 cells/well into 6 well plate. Cells were 
allowed to adhere for 24 hours, then were treated for 6, 16 and 24 hours with 
vehicle alone (N/T) or with XM462, d2-C8-dhCER or Revs (see figure legends for 
treatment conditions). Total RNA was extracted with RNA extraction column kit 
(Promega), and 1 µg of RNA was reverse transcribed in cDNA using M-MLV 
Retrotranscriptase using oligo dT primers (Promega). The reaction was performed 
in a final reaction volume of 20 µl incubating samples for 2 min at RT, followed by 
an incubation at 37°C for 45 min, then heated up at 42°C for 45 min. From the 
resulting cDNA, 25ng were amplified using GoTaq Poymerase (Promega) with 
primer pair that recognizes both unspliced and spliced XBP-1: forward primer 5’-
GTTGAGAACCAGGAGTTAAGA -3’ and reverse primer 5’-
CATTAATGGCTTCCAGCTTGG-3’. The PCR reaction occurred in a final volume of 
25 µl and it was performed using a GeneAmp PCR system 2770 (Applied 
Biosystem) with thermal cycler protocol: 1 cycle at 94°C for 2 min; 25 cycles at 
94°C for 30 sec, 55°C for 1 min, 72°C for 30 sec; 1 cycle 72°C for 5 min. 
Amplification products were separated by electrophoresis in a 1.25% acrylamide 
gel subjected to 90 volts for 2 hours and 30 min. 
2.12 Statistical analysis 
Data significance was evaluated by either t student test at p<0.05 or one-way 
ANOVA followed by the Bonferroni multiple comparisons if ANOVA significant 
(p<0.05). The western blottings presented are the most representative of at least 
three independent experiments. For densitometry quantification, data were 
acquired from three independent experiments and the medium value ± standard 
deviation was reported. 
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3. RESULTS 
3.1 Resveratrol does not induce apoptosis and death in HGC-27 
cells 
Resveratrol exhibits a double face on cell life/death regulation; from one hand it is 
able to induce cell death, from the other hand, simulating a calorie restriction state, 
it triggers cell viability (for review see [224]). In order to test resveratrol effect on 
HGC-27 cell line, we measured proliferation in compound treated cells by SRB 
assay (Fig. 1, panel A). HGC-27 cells were treated with resveratrol, at 16 and 32 
µM, and its effect on cell proliferation was detected 2, 3, or 6 days after treatment. 
The resveratrol treatment resulted in HGC-27 cell proliferation reduction within 6 
days in a dose depending manner. Resveratrol did not affect HGC-27 cell survival 
within 48 hours after treatment, as revealed by trypan blue exclusion test (Fig. 1, 
panel B). To confirm the absence of resveratrol cytotoxic effect on HGC-27 cells, 
we evaluated, by western blotting analysis, the absence of cleaved poly-adenine-
ribose polymerase (PARP), the terminal caspases target (Fig 1, panel C). PARP 
cleavage was not evident in HGC-27 cells treated for 16 and 24 hours with 50 µM 
resveratrol. Using the same treatment condition for the MDA-MB 231 breast 
carcinoma cells, which were used as positive controls [4], PARP cleavage revealed 
that apoptosis was already induced 16 hours after resveratrol treatment (Fig. 1, 
panel C). All these data suggest that resveratrol had an effect on HGC-27 cell 
proliferation that, at least within 48 hours after treatment, is not associated with cell 
death. Previous studies from our laboratory showed that resveratrol-induced cell 
death is mediated by ceramide accumulation and signaling [4, 225]. From liquid-
chromatography coupled to mass spectrometry (LC-MS) analysis we observed that 
treatment of HGC-27 cell line with resveratrol did not induce ceramide 
accumulation, but a high and dose dependant increase of the ceramide precursor, 
dihydroceramide was observed (Fig. 1, panel D).    
3.2 Resveratrol induces a dihydroceramide accumulation 
comparable to that induced by XM462 
We next compared the effect of resveratrol with that of the specific inhibitor of 
DEGS-1 enzymatic activity (XM462) on intracellular concentration of 
dihydroceramide and ceramide species. Liquid-chromatography coupled to mass 
spectrometry (LC-MS) was performed to analyze total sphingolipids extracts from 
HGC-27 cells treated with resveratrol (50 µM) or XM462 (8 µM) for 16 and 24 
hours. Treatment with resveratrol for 16 hours was able to induce an 8 fold 
increase over untreated cells in total dihydroceramides. The resveratrol effect on 
dihydroceramides accumulation was comparable with XM462 (Fig. 2, panel A). The 
resveratrol and XM462 treatment did not affected total ceramides amount. 
Interestingly, N-C16 acyl chain specie exhibited higher increase compared with the 
other dihydroceramides under  both resveratrol and XM462 (Fig. 2, panel B, 
bottom). The dihydroceramides accumulation persisted 24 hours after treatment, 
even if its magnitude was lower than that reported at 16 hours 
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Fig. 1 Resv did not induce HGC-27 cell death. A) HGC-27 cell proliferation was 
assessed by SRB assay. Cells were analyzed after 2, 3, or 6 days of treatment with 
the vector only (0.1% ethanol) (N/T), 25 or 50 µM Resv, dissolved in ethanol. Cell 
proliferation was described using an exponential trend line. B) HGC-27 cells 
viability was assessed, by Trypan blue exclusion test, immediately before treatment 
(time 0) or after 16, 24 or 48 hours of treatment with 50 µM Resv. Values from 
three samples, reported as average ± SD, were calculated as ratio of a live cells 
over total counted cells. C) HGC-27 and MDA-MD-231 cells were treated for 16 or 
24 hours with the vector only (0.1% ethanol) (-) or with 50 µM Resv (+). The 
cleaved form of PARP was assessed as apoptotic marker. The western blottings 
presented are the most representative of three independent experiments. D) HGC-
27 cells were treated for 24 hours with the vector only (0.1% ethanol) (N/T) or with 
25 or 50 µM Resv. Total ceramide and dihydroceramide were extracted and 
analyzed by LC-MS. Fold increase over N/T are reported as average ± SD, 
calculated from three samples. Statistical significance was calculated using a two-
tail Student T-test (p<0.05). 
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We speculated that resveratrol increases dihydroceramides endogenous level by 
inhibiting DEGS-1 enzymatic activity. To prove this hypothesis, desaturase activity 
was measured in homogenates of HGC-27 cells previously treated with resveratrol 
for 16 and 24 hours. Resveratrol dramatically reduced the DEGS-1 activity, 
showing an inhibitory action on desaturase comparable with the effect of XM462. 
The inhibition of both resveratrol and XM462 on DEGS-1 action persisted up to 24 
hours after treatment (Fig. 2, panel C).  
 
 
Fig. 2 Resv DEGS-1 inhibition and dihydroceramide accumulation was 
comparable with XM462. HGC-27 cells were treated for 16 and 24 hours with the 
vector only (0.1% ethanol) (N/T), with 50 µM  Resv or 8 µM XM462. Total lipids 
were extracted and both ceramide and dihydroceramide species were quantified by 
LC-MS. A) The fold increase of total ceramides and dihydroceramides calculated 
as ratio of treated cells versus N/T is reported. B) The amount (picomoles) of the 
single species of ceramides and dihydroceramide, normalized over the mg of 
proteins, is reported. C) The dihydroceramide desaturase activity was evaluated in 
cells homogenates. In all cases, data were obtained from three experiments and 
values were expressed as the avarage ± SD. Data significance was evaluated by 
either t student test at p<0.05 or one-way ANOVA followed by the Bonferroni 
multiple comparisons if ANOVA significant (p<0.05) 
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3.3 Dihydroceramide accumulation does not induce cell death. 
Recently dihydroceramide has been proposed as a molecule involved in cell 
signaling. 
In order to understand if dihydroceramide accumulation and survival observed in 
resveratrol treated cells was due to a resveratrol side effect or to the direct 
signaling induced by dihydroceramide, we investigated the effect of DEGS-1 
inhibitor XM462 on cell survival. Cells viability, assessed using trypan blue 
exclusion test, was not affected after 48 hours treatment with any of the XM462 
concentration used. (Fig. 3, panel A). Moreover the absence of cleaved PARP, 
analyzed by western blotting on HGC-27 cells treated for 24 hours with XM462, 
confirmed that the dihydroceramide accumulation is not cytotoxic. We excluded the 
possibility of  apoptosis deficiency in our cell line by detecting PARP cleavage after 
50 µM etoposide treatment for 24 hours (Fig.3, Panels B). Interestingly, 
proliferation studies by SRB assay (Fig. 3, panel C) showed a dose dependant 
proliferation delay upon XM462 treatment, similarly to resveratrol treatment.  
Therefore, we ought to investigate XM462 action  by cell cycle analysis using 
propidium iodide (PI) DNA staining (Fig. 3, Panels D). HGC-27 cells, treated with 5 
µM XM462 for 8, 16 and 24 hours, did not show a significant apoptosis induction 
compared to the control population (N/T) (Fig. 3, panel D). These data suggested 
that dihydroceramide accumulation, obtained treating cells with a specific DEGS-1 
inhibitor, was not able to trigger an apoptosis mediated cell death and did not 
influence cell viability. 
Merrill and co-workers proposed that the antitumoral drug fenretinide (4-HPR) is 
able to induce dihydroceramide accumulation in MCF-7 cells associated with 
autophagy cell death [8]. 
Moreover dihydroceramide accumulation obtained in human neuroblastoma cell 
line either after transient DEGS-1 silencing or 4-HPR treatment inhibited cell 
growth through cell cycle arrest in G0/G1 phase [9]. On the other hand, 
dihydroceramide was reported to have an anti-apoptotic role by preventing  
ceramide-mediated channel formation in isolated mitochondria [10].  
Thus dihydroceramide signaling is still unknown and might induce a different effect 
according to cellular settings. 
In order to tight the link between resveratrol and dihydroceramide induced effects, 
we compared the treatment with XM462 and the non specific dihydroceramide 
inducer 4-HPR in HCG-27 cells. Knowing from previous studies reported in the 
literature that treatment in the micromolar range of tumoral cell line with 4-HPR are 
able to trigger dihydroceramide accumulation [8, 9, 100], HGC-27 cells were 
treated with 4-HPR (1, 5, 10 µM) and XM462, viability was investigated, using 
Trypan blue exclusion test. Treatment with 4-HPR at 1 µM did not affect HGC-27 
cell viability (Fig. 3, panel E). Increasing 4-HPR concentration at 5 µM, we 
observed a reduction in cell viability between 48 and 72 hours after treatment. 
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Fig. 3 The effect of dihydroceramide accumulation on cell viability and cell 
death. A) HGC-27 cells viability was assessed, by Trypan blue exclusion test, 
immediately before treatment (time 0) or after 24, 48, or 72 hours of treatment the 
vehicle only (0.1% ethanol) (N/T), with 4 or 8 µM XM462. Values from three 
samples, reported as average ± SD, were calculated as ratio of live cells over total 
counted cells. B) HGC-27 cells were treated for 16 or 24 hours with the vehicle only 
(0.1% ethanol) (N/T), with 0.5, 1 or 5 µM XM462, or 50 µM etoposide (Etp). The 
presence of the cleaved form of PARP was assessed as apoptotic marker. To 
verify the loading homogeneity, the housekeeping protein β-actin was also 
detected. The western blottings presented are the most representative of at three 
independent experiments. C) HGC-27 cell proliferation was assessed, by SRB 
assay, after 2, 3, or 6 days of treatment with the vector only (0.1% ethanol) (N/T), 4 
or 8 µM XM462. Cell proliferation index values are reported as average ± SD and 
proliferation is described using an exponential trend line. D) HGC-27 cell cycle was 
analyzed immediately before treatment (time 0), 8, 16 and 24 hours after treatment 
with 5 µM XM462 using PI staining (PI) DNA staining. Events detected for FL2 
signal was reported in logarithm scale (FL2-H). Experiment reported was the most 
representative of three. E) HGC-27 cells viability was assessed, by Trypan blue 
exclusion test, immediately before treatment (time 0) or after 24, 48, or 72 hours of 
treatment the vector only (0.1% ethanol) (N/T), with 1, 5 or 10 µM 4-HPR. Values 
from three samples, reported as average ± SD, were calculated as ratio of live cells 
over total counted cells. Data significance was evaluated by either t student test at 
p<0.05. 
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The cytotoxic effect on HGC-27 cells was exacerbated increasing 4-HPR 
concentration up to 10 µM, concentration significantly reduced cell viability 
between 24 and 48 hours after treatment (Fig. 3, panel E). Such dose dependant 
toxicity of 4-HPR is in agreement with the observation that 4-HPR acts on 
sphingolipid pathway inhibiting DEGS-1 activity but also inducing a concomitant 
SPT and CERSs activation as well as B-CDase2 overexpression [76, 100]. 
Treatment with this drug leads to the accumulation of dihydroceramide but also of 
Sa, a molecule with cytotoxic properties, and its phosphorylated form, Sa1P, 
molecule with putative pro-survival properties. Wang and coworker proposed a 
compensatory effect between Sa and Sa1P, and suggested that the 4-HPR  
cytotoxic effect could be explained by the increase ratio between Sa and Sa1P 
[100]. Our hypothesis is that dihydroceramide immediate accumulation may not 
trigger cell death but the accumulation of Sa byproducts may do that at higher 
doses. 
3.4 Resveratrol and XM462 induce autophagy in HGC-27 cells 
Preliminary data reported that resveratrol is associated with autophagy induction in 
MCF-7 cells, followed by cell death [7]. Autophagy has a dual outcome: from one 
hand it is implicated in cell protection and survival; on the other hand its  massive 
and prolonged induction leads to cell death, also known as Type II cell death [202].  
Autophagy induction was evaluated in HGC-27 cells treated with different 
concentration of resveratrol, detecting the accumulation of the autophagosome 
membrane component LC3-II (the conjugated product of LC3-I to 
phosphatidylethanolamine). Resveratrol was able to induce autophagy in a dose 
dependant manner (Fig. 4 panel A). To verify the role of dihydroceramide in 
autophagy induction, we treated HGC-27 cells with increasing concentration of 
XM462. It resulted in a dose dependent manner LC3-II accumulation, suggesting 
that dihydroceramide is implicated in autophagy induction (Fig. 4 panel B). To 
understand the timing in autophagy induction, HGC-27 cells were treated in parallel 
with resveratrol and XM462 and LC3-II accumulation was analyzed 3, 6 and 16 
hours after treatment. The specific DEGS-1  inhibitor rapidly induced autophagy in 
HGC-27 cells, leading to the accumulation of LC3-II within 6 hours after treatment 
at 5 or 10 µM XM462. Resveratrol induced autophagy only after 16 hours of 
treatment (Fig. 4 panel C). In addiction the co-treatment of either resveratrol and 
XM462, with 3-methyladenine (3MA), an PI3K type III complex  inhibitor [226], 
abrogated LC3 conjugation with PE confirming the data above reported (Fig. 4, 
panel D). LC3-II could accumulate in two circumstances: an increase of autophagy 
or a reduction of its lysosomal clearance [227]. Hence, LC3-II was analyzed after 
co-treatment of resveratrol or XM462 with the lysosomal protease inhibitor 
leupeptin and pepstatin A (LP). Co-treatment with LP increased LC3-II 
accumulation mediated by resveratrol and XM462, confirming that the two 
compounds are able to enhance the autophagy flux (Fig.4 panel E).  
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Fig. 4 Resveratrol and XM462 promoted autophagy. Autophagy induction 
evaluation of LC3-II by western blotting from HGC-27 cells. To verify the loading 
homogeneity the housekeeping protein β-actin was also detected. A) Cells were 
treated for 16 or 24 hours the vector only (0.1% ethanol) (N/T), with 25 or 50 µM 
Resv. B) Cells were treated for 24 hours with the vector only (0.1% ethanol) (N/T) 
or  with 0.8, 2, 4 or 8 µM XM462. The band density was measured and increase of 
N/T was evaluated. C) Cells were treated for 3, 6 or 16 hours with the vector only 
(0.1% ethanol) (N/T), with 5 or 10 µM XM462 or with 50 µM Resv. D) Cells were 
treated for 24 hours with the vector only (0.1% ethanol) (N/T), with 8 µM XM462 or 
with 50 µM Resv, alone or in co-treatment with 5 µM 3MA. E) Autophagy flux 
induction was evaluated treating cells for 16 or 24 hours with 50 µM Resv, 8 µM 
XM462 or starved in serum and non essential aminoacids free medium (Starv), in 
presence or absence of 10 µg/ml of each protease inhibitors Leu and PepA (LP). 
F) GFP-LC3 localization in HGC-27 cells transfected with GFP-LC3 containing 
plasmid, rested for 24 hours and then treated with 10µg/ml of protease inhibitors 
(Leu+PepA), 50 µM Resv, 8 µM XM462. Treatment with 1 µM rapamycin, or 
starvation were used as autophagy positive controls (40x magnification). 
 
 
To further confirm that these molecules were able to induce autophagy, the 
subcellular localization of GFP-LC3 protein after transient transfection and its 
accumulation in autophagosomes upon treatment was also analyzed. HGC-27 cells 
were transiently transfected with a LC3-GFP conjugate containing vector and 24 
hours after transfection, cells were treated for 24 hours with resveratrol or XM462.  
As a positive control of autophagy induction we used the direct mTOR inhibitor 
rapamycin or serum and non essential aminoacids starvation. As a further positive 
control, we treated cells with LP that induces intra cytoplasmic GFP-LC3 dots due 
to the inhibition of lysosomal clearance of autophagosomes. Fluorescence 
microscopy revealed that in negative control the fluorescence was diffused in the 
cytoplasm. Both resveratrol and XM462 were able to induce the formation of intra 
cytoplasmic GFP-LC3 dots in a fashion similar to the positive controls (Fig.4 panel 
F). All these data demonstrate that both resveratrol and XM462 induced 
autophagy, and strongly suggest that their action is due to the dihydroceramide 
increase. 
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Finally we evaluated autophagy induction in HGC-27 in response to other 
compounds previously known to trigger dihydroceramide accumulation (Fig. 5, 
panel A). Treatment with 5 µM 4-HPR, a concentration known to induce 
dihydroceramide accumulation in several cell lines [8, 9, 112], induced LC3-II 
accumulation within 24 hours of treatment. HGC-27 growth under hypoxic 
condition, that have been shown to induce dihydroceramide accumulation in 
tumoral cells [228], showed autophagy activation 24 hours after treatment. 
Moreover, treatment with 2.5 µM of the natural marine compound, jaspine B, that 
induces  dihydroceramide accumulation in A549 human lung carcinoma cell line 
[229], strongly activated autophagy already 16 hours after treatment.  
In order to prove that dihydroceramide exerts a direct effect on autophagy 
induction, we treated cells with a short chain dihydroceramide analogue that can 
not be metabolized into complex sphingolipids neither hydrolyzed. Treatment with 
2.5 µM of d2-C8-dhCER revealed LC3-II accumulation after 24 hours . All together 
these data reinforce the finding that dihydroceramide accumulation is tightly 
connected to autophagy activation and that dihydroceramide maybe a direct 
activator of autophagy. 
In order to demonstrate  that the effect of dihydroceramide on autophagy activation 
is not exclusive of HGC-27 cell line, we evaluated its effect also in the breast 
cancer cell line MCF-7. This cell line was treated for 16 and 24 hours with  5 µM 
XM462 or 5 µM 4-HPR or with the hypoxic mimetic cobalt chloride (CoCl2) 0.4 µM. 
All these treatments showed autophagy activation (Fig. 5, panel B). 
 
 
 
Fig. 5 Drugs inducers of dihydroceramide accumulation are also autophagy 
inducers. A) HGC-27 cells were treated with for 16 or 24 hours with 5 µM 4-HPR, 
2.5 µM jaspine B, 2.5 µM d2-C8-dhCER or grew under hypoxic condition. B) MCF-
7 cells were analyzed 16 and 24 hours after treatment with 5  µM XM462, 5 µM 4-
HPR, 0.4 µM CoCl2 or grew in hypoxic condition. 
Values were reported as increase over time 0, cells analyzed immediately before 
treatment.  
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3.5 Dihydroceramide accumulation induces a transient cell cycle 
arrest 
Cells respond to stress, such as nutrient depletion, hypoxia and unfolded protein 
accumulation, activating a plethora of cellular mechanisms necessary to the 
adaptation to the new environment. Autophagy is a major strategy in this response 
and several evidences demonstrate that its activation is accompanied by cell cycle 
arrest [230, 231].   
Silencing of DEGS-1 gene expression in neuroblastoma cell line induces cell cycle 
arrest in G0/G1 phase within 16 hours [9], suggesting that dihydroceramide could 
be involved in cell cycle regulation.  
Therefore we analyzed the modulation of sphingolipids intracellular amount 
following XM462 treatment in HGC-27 cells. This modulation was correlated with 
variations in cell cycle progression. For such studies we synchronized cells using 
nocodazole (a pharmacological agent that blocks microtubules polymerization, 
arresting cells at the G2/M phase entry). 
Once released from synchronization, by nocodazole removal, HGC-27 cells 
proceeded along cell cycle. 4 hours after release, cells moved from G2/M to G0/G1 
phase, peaking in this next phase 8 hours after release. Untreated cells, peaked in 
S and G2/M phases within 16 hours after release, and newly in G0/G1 phase at 24 
hours (Fig. 6 panel A and B).The synchronization was maintained by the cells for 
72 hours (data not shown). XM462, treatment immediately at the release from  
nocodozole, induced a dihydroceramide accumulation that was able to perturb 
HGC-27 cell cycle progression with an anti-proliferative effect inducing a stop-and-
go effect on cell cycle progression. The anti-proliferative effect was detected 
between 4 and 16 hours, when XM462 treated cells accumulated and remained in 
G0/G1 phase, whereas untreated cells started to flow through S phase (after 8 
hours from release). This effect was only transient, causing  a delay in cell cycle 
progression, because treated cells moved to S phase  from 16 hours onwards. The 
progression from S and G2/M required the same time of  untreated cells, peaking 
again in G1phase after 32 hours (with an approximately 8 hours delay in respect to 
untreated cells). Thus dihydroceramide prolonged the permanence of cells in the 
G0/S bounderies and this delayed synchronization was maintained until 72 hours 
(data not shown).  
The XM462 action between 4 and 16 hours was confirmed by the cyclin D1 and E 
analysis by western blotting (Fig. 6 panel C). Cyclin D1 conjugates with CDK4 and 
induces pRb phosphorylation and triggers cell cycle progression from G1 to S 
phase [134]. Cyclin D1 accumulation begins the cascade of events necessary to 
proceed with DNA replication during S phase. Untreated cells accumulated this 
protein at 8 and 24 hours after treatment, right at the time in which they passed 
from one G1 peak through the following cycle phases. On the contrary, cells did not 
accumulate cyclin D1 within the first 16 hours of XM462 treatment, resulting in a 
prolonged peaking at G0/G1. Later on, we detected an increase of cyclin D1, 
reaching a maximum at 24 hours, demonstrating that cells were still effectively able 
of  progression along cell cycle. Cyclin E is a late G1 phase protein whose activity 
depends on its conjugation with CDK2 and it is degraded during S phase 
progression. Protein analysis revealed that in untreated control cells it accumulated 
within 8 hours after release, together with cells exit from G0, flowing to S. Cells 
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treated with XM462 exhibited a cyclin E peak at 16 hours delayed of approximately 
8 hours from control cells, mirroring the 8 hours delay of cycle phases progression. 
To investigate whether dihydroceramide rather than one of its metabolites 
accumulation was able to induce the effect on cell cycle progression, the amount of 
sphingolipids species in nocodazole synchronized HGC-27 cells were measured 
using LC-MS at 0, 4, 8, 16, 24 and 32 hours after release with or without XM462. 
Analysis revealed that dihydroceramides accumulated in HGC-27 cells treated with 
XM462, having a peak 4 hours after release; then dihydroceramides level slightly 
decreased, returning to the original concentration at 24 hours after treatment (Fig.7 
panel A). Ceramides did not increase between 8 and 48 hours after release (Fig.7 
panel A) confirming that the desaturation block  forced dihydroceramides 
metabolism in other sphingoid species starting from 4 hours after treatment 
onward. By analyzing different dihydroceramides metabolites, we found out that 
dihydrosphingomyelin species rapidly accumulated, reaching  a peak 8 hours after 
release,  remaining almost stable at all the analyzed times (Fig.7 panel B). The 
other two dihydroceramide metabolites dihydro-lactosyl-ceramide and dihydro-
glucosyl-ceramide slightly accumulated after XM462 treatment, peaking 16 hours 
after release and then slowly decreased (Fig.7 panel C and D). Finally, 24 hours 
after release, sphinganine accumulated in HGC-27 cells (Fig.7 panel E). From such 
evidences we can conclude that dihydroceramide  was at first metabolized in 
dihydrosphingomyelin that accumulated already 8 hours after release, only 
successively dihydro lactosyl- and glucosyl- ceramides grew up, peaking at 16 
hours.The last sphingolipid to peak was sphinganine. We speculate that the delay 
of the cell cycle, focused within 16 hours after XM462  treatment, was due to the 
dihydroceramide accumulation (already present at 4 hours of treatment) rather than 
to the action of other metabolites. 
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Fig. 6 Dihydroceramide induce a transient cell cycle arrest. HGC-27 cells were 
synchronized in G2/M phase treating for 10 hours with nocodazole 0.2 µM.  
Synchronized cells were released from NOC-mediated synchronization replaced  in 
fresh media in presence (NOC+XM) or absence (NOC) of 8 µM XM462. DNA was 
stained with PI and cell cycle was analyzed by flow cytometry immediately before 
the release (time 0), 4, 8, 16, 24 and 32 hours after release. A) Overlay histogram 
from NOC (gray) and NOC+XM (black line) samples. Histogram was reported as 
counted  events detected and FL2 signal reported in linear scale (FL2-A). The 
experiment reported was the most representative of three. B) Events quantified for 
each phase and calculated from three different experiments, were reported as 
percentage over total analyzed events. C) Cyclin D1 and cyclin E amount, reported 
as increase over time 0, were detected by western blotting and reported as bands 
intensity value normalized over β-actin. 
Data significance was evaluated by t student test at p<0.05. 
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Fig. 7 Sphingolipids metabolism after XM462 treatment. Total lipid extract from 
HGC-27 cells synchronized in G2/M phase by a 10 hours treatment with 0.2 µM   
nocodazole. Synchronized cells were released from NOC-mediated 
synchronization by replacing fresh media in the presence (NOC+XM) or absence 
(NOC) of 8 µM XM462. Total amount of different species of ceramide, 
dihydroceramide, sphingomyelin, dihydrosphingomyelin, glucosyl- (Glc) ceramide, 
Dihydro-Glc-ceramide, galactosyl- (Gal) ceramide, Dihydro-Gal-ceramide, lactosyl- 
(Lac) ceramide, Dihydro-Lac-ceramide, sphingosine and sphinganine were 
analyzed by LC-MS immediately before the release (time 0) or 4, 8, 16, 24 and 48 
hours after release. Values were reported as sphingolipids fold increase over 
 time 0. 
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This finding was confirmed by the observation that treatment with 20 µM d2-C8-
dhCER, resulted in HGC-27 cell cycle arrest in G0/G1 phase. In fact the amount of 
treated cells in G0/G1 phase increase of 60%, compared with untreated cells. The 
presence of a discrete amount of cells in S phase concomitantly with a sensible 
reduction of cells in G2/M phase after treatment suggest that cells were transiently 
arrested in G0/G1 phase, and proceeded throughout cell cycle within16 hours, 
probably as soon as dihydroceramide was cleared by sphingolipid metabolism. 
(Fig. 8) 
 
 
 
 
 
Fig. 8 Non-metabolized deuterated-dihydrocesramide analogue induces cell 
cycle delay. HGC-27 cells were synchronized in G2/M phase by a 10 hours 
treatment with 0.2 µM nocodazole.  Synchronized cells were released from NOC-
mediated synchronization by replacing cells in  fresh media in the presence 
(NOC+d2-C8-dhCER) or absence (NOC) of 20 µM d2-C8-dhCER. Cells were 
stained with PI and cell cycle was analyzed by flow cytometry 16 hours after 
release. A) The counted  events, detected as FL2 signal in linear scale (FL2-A), are 
reported as overlay histogram from NOC (gray) and NOC+d2-C8-dhCER (black 
line) samples. B)  Events were quantified for each phase and reported as 
percentage over total analyzed events. 
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3.6 Dihydroceramide-induced autophagy is associated an ER 
stress response activation. 
Stress stimuli, such as glucose deprivation, hypoxia and oxidative stress lead to 
the accumulation of unfolded proteins in the endoplamic reticulum (ER). Cell 
responds to ER engulfment activating a transcriptional and translational response, 
known as unfolded proteins response (UPR), an adaptive mechanism that 
regulates both survival and death effectors. An increasing number of studies 
indicate that autophagy and cell cycle arrest are induced by ER stress. Since the 
de novo synthesis of ceramide is located in ER [45], and that dihydroceramide 
transport from ER is about 40% slower than ceramide [108], we assumed that 
dihydroceramide accumulation into ER leads to an ER stress response.  
To demonstrate this hypothesis, intracellular trafficking of C6-dihydroceramide and 
ceramide conjugated with a fluorophore (7-nitrobenz-2-oxa-1,3-diazole; 
respectively NBD-dhCER and NBD-CER) were assessed by confocal microscopy 6 
and 16 hours after treatment. NBD fluorescence for both NBD-CER and NBD-
dhCER (green signal), resulted localized into the ER, labeled with a specific tracker 
(red signal) after 6 hours treatment. Difference in NBD-CER and NBD-dhCER 
intracellular localization was reported 16 hours after treatment. While NBD-CER 
fluorescence signal moved into Golgi apparatus and plasma membrane, NBD-
dhCER fluorescence signal was retained inside the ER compartment (Fig 9 panel 
A). These data confirm that also in our experimental model, the transport from ER 
to Golgi is more efficient for ceramide then dihydroceramide which, at list until 16 
hours, accumulated inside ER.  
To test whether dihydroceramide accumulation induced ER stress triggering UPR,  
HGC-27 cells were treated with XM462 and ER stress was investigated 8, 16 and 
24 hours after treatment analyzing the XBP-1 splicing.  
Treatment with the positive control tunicamycin induced UPR and XBP-1 splicing in 
HGC-27 at all the time point analyzed (data not shown). XM462, leading 
dihydroceramide accumulation within 4 hours after treatment, induced a significant 
XBP-1 splicing at the earliest time point. Splicing index in fact resulted statistically 
different from untreated cells only in samples analyzed 8 hours after treatment, 
while no significant difference was reported 16 and 24 hours after treatment. This 
evidence is in agreement with the hypothesis that dihydroceramide induced 
autophagic response is able to overcome a stress and to warren cell survival.  
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Fig. 9 Dihydroceramide accumulated at the ER and induces ER stress. A) 
HGC-27 cells, treated with 5 µM of NBD-C6-ceramide (NBD-CER) or NBD-C6-
dihydroceramide (NBD-dhCER) (green) in co-treatment with 0.5 µM ER tracker 
(red), were analyzed 6 or 16 hours after treatment by confocal microscopy. NBD-
dhCER, but not NBD-CER, co-localized (yellow) with ER tracker until 16 hours after 
treatment. B) XBP-1 splicing from HGC-27 cells analyzed immediately before 
treatment (time 0), 6, 16 or 24 hours after treatment with 8 µM XM462, or 25 µM 
d2-C8-dhCER; cells treated with 50 µM Resv were analyzed after 6 or 24 hours 
after treatment. Unspliced XBP-1, upper band, were resolved from spliced XBP-1, 
lower band, by a 1.25% acrylamide gel. Splicing index, calculated as ratio of 
spliced versus unspliced XBP-1 values, were reported as average ± SD from three 
different experiments. Statistical significance by 2-tails T-test with p≤ 0.05. C)  
Autophagy during ER stress was investigated analyzing LC3-II in HGC-27 cells 
treated for 24 hours with 50 µM  Resv,  8 µM XM462 and 1 µg/ml tunicamycin 
(Tuni). Values of LC3-II, normalized over β-actin, were reported as fold increase 
over untreated cells (N/T). 
 
 
 
To confirm the dihydroceramide effect as ER stress inducer, HGC-27 cells where 
treated with the deuterated dihydroceramide analogue d2-C8-dihydroceramide (d2-
C8-dhCER), a dihydroceramide analogue that can not be metabolized in other 
sphingolipids. Treatment with this molecule also induced XBP-1 splicing in 24 
hours. The different time frame of ER stress induction may be related to the 
difference of the molecular pools (natural dihydroceramides versus short chain 
exogenous dihydroceramides) and to the required time for cellular uptake of the 
analogue. These data were also enforced by results obtained treating HGC-27 with 
resveratrol, that induced a XBP-1 splicing at 8 and 24 hours with a trend 
comparable to XM462 and d2-C8-dhCER (Fig. 9 panel B). All these data 
suggested that dihydroceramide accumulation is associated with ER stress 
induction. 
To confirm that UPR activation is able to induce autophagy in our cell model, we 
treated HGC-27 cells for 24 hours with tunicamycin, a drug known to induce ER 
stress. This treatment resulted in an autophagy induction comparable with that 
observed under XM462 and resveratrol treatment (Fig. 9 panel C). 
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4. DISCUSSION 
Objective of my doctorate project was to investigate on the biological role and the 
potential signaling activity of dihydroceramide.   
Data from our laboratory in the gastric cancer cell line HGC-27 suggest that 
resveratrol, a polyphenol known for its anti-tumoral and antioxidant properties, is a 
good inducer of dihydroceramide. The results of my doctorate research have been 
partially published on Cancer Letters [232] and are included in a second 
manuscript in preparation.  
 
Gastric epithelial cancer represents a suitable model to study the anticancer 
properties of resveratrol, being the gastrointestinal tract directly exposed to the 
native compound at the highest dietary concentration prior to its rapid glycosylation 
in the blood for further elimination. Surprisingly, treatment of the gastric epithelial 
cancer cell line HGC-27 with resveratrol did not affect cell viability (Fig.1, panel B 
and C), even when it was used at higher concentration than those that induced 
death in other cancer cells. Several authors, including us, described resveratrol 
anti-proliferative and pro-apoptotic activity in a variety of cancer cell lines as a 
consequence of the induced accumulation of ceramide and its signaling to either 
apoptosis- [4, 225] or autophagy-  [7].mediated cell death.  
Indeed resveratrol was not able to induce ceramide accumulation in HGC-27 cells, 
addressing us to hypothesize that these cells may switch on a putative resistance 
mechanism. 
From the other hand HGC-27 maintained a sensitivity to resveratrol, which was 
able to exert anti-proliferative effect as shown by the reduction of cellular 
proliferation by SRB test (Fig. 1, panel A). This cell line responds to resveratrol 
treatment by increasing significantly the spontaneous base line level of autophagy. 
Autophagy increase was dose dependant to resveratrol treatment, as 
demonstrated by LC3-II accumulation and GFP-LC3 autophagosome-lysosome 
location (Fig. 4). Again, autophagy was not associated with cell viability decrease. 
Several authors described resveratrol as a cell survival inducer, working as a 
calorie restriction mimetic molecule that enhances SIRT-1 activity, increasing life 
spam in metazoans as well as in other organisms [213, 233, 234]. Any nutrient 
restriction, glucose and aminoacids, together with oxygen restriction, is tightly 
linked to enhanced autophagy in order to reduce cell demand and proliferation. 
Thus we investigated on resveratrol induced autophagy and sphingolipid 
metabolism in HGC27. 
Peculiar of HGC-27 response to resveratrol is the effect on sphingolipid metabolic 
pattern. HGC-27 treated with resveratrol, in fact, did not accumulate ceramide, 
instead they accumulated its saturated form, dihydroceramide, which reached a 10 
fold increase over control in the C16-dihydroceramide species (Fig. 2 panel A and 
B). This form derives from sphingolipid de novo synthesis and can be next 
metabolised in the other forms with longer and/or desaturated acyl chains. Thus 
resveratrol is able to block sphingolipid metabolism in a specific step of their de 
novo synthesis. 
We found that resveratrol blocked the dihydroceramide desaturation into ceramide, 
reaction catalyzed by DEGS-1. The action of resveratrol was evident at 16 hours 
and increased its potency at 24 hours of treatment. Resveratrol effect is 
comparable with that induced by a specific DEGS-1 inhibitor XM462 (Fig. 2 panel 
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C). The resveratrol-mediated DEGS-1 activity inhibition may be linked to the 
cellular balance of NAD(P)+/NAD(P)H+H+. Desaturation reaction, catalyzed by 
DEGS-1, requires NADPH+H+ oxidation and oxygen reduction. Although the rate 
limiting step in the de novo sphingolipid synthesis is the serine-palmitate 
condensation, the desaturation of dihydroceramides may offer another important 
checkpoint governed by cell metabolism and energy state changes, which would 
depend on the of NAD(P)+/NAD(P)H+H+  ratio and oxygen levels. We hypothesized 
that resveratrol, either directly or indirectly, mimicking a calorie restriction condition 
and changing the energy and redox cell state, could down regulate desaturase 
activity. This hypothesis is also corroborated by the observation that oxidative 
stress induced by H2O2, tert-butylhydroperoxide (an hypoxia mimicking agent) and 
menadione (an intracellular ROS inducer) inhibit DEGS-1 activity [235], and that 
depletion of cellular level of thiols result in a DEGS-1 activity inhibition [49].  
Recent data reported from several groups described a contradictory role for 
dihydroceramide: from one hand it seems to be involved in pro-death mechanism 
[8, 9], on the other hand it induces pro-survival effect [10]. 
A few studies used 4-HPR, a drug known for its pro-apoptotic [236] and growth 
inhibitory [237] effect on tumoral cells, as a strategy for inducing dihydroceramide 
accumulation. Merrill and co-worker proposed that dihydroceramide accumulation 
after 4-HPR treatment of DU145 cell was associated with autophagic cell death [8]. 
In addiction, the dihydroceramide accumulation following the transient gene 
expression silencing of DEGS-1 in a neuroblastoma cell line was recapitulated by 
treatment with low concentration of 4-HPR. Both treatments resulted in the arrest of 
cell cycle at the G0/G1 phase and consequently to growth inhibition [9]. 
From the other hand the anti-apoptotic role of dihydroceramide was also proposed, 
describing dihydroceramide action in prevention of ceramide-mediated channel 
formation in isolated mitochondria [10].  
In the gastric cancer cell line HGC-27, resveratrol induced dihydroceramide 
accumulation instead of ceramide (Fig. 1, panel D). Similarly to resveratrol, 
treatment with DEGS-1 specific inhibitor XM462, in order to accumulate 
dihydroceramide, was not associated with any cell viability reduction, cell death or 
apoptosis induction (Fig. 3 panel B).  
Dihydroceramide accumulation following the treatment of HGC-27 cells with 
XM462, resulted in autophagy induction 6 hours after treatment. Autophagic flux 
increased in a time and a dose dependent manner until 24 hours of treatment (Fig. 
4). Taking into account that XM462 was able to induce a dihydroceramide peak 4 
hours after treatment, earlier than autophagy, we can conclude that autophagy 
induction is downstream of dihydroceramide signalling. 
When we treated cells with a non specific dihydroceramide inducer, 4-HPR we 
obtained the same enhancement of autophagy (Fig. 5 panel A), confirming that the 
common mediator dihydroceramide is linked to autophagy induction. We also 
noticed a dose dependent effect on cell viability (Fig. 3 panel A). 4-HPR in fact acts 
on sphingolipid pathway inhibiting DEGS-1 activity but also inducing a concomitant 
activation of the SPT, of CERSs and B-CDase2 [76]. For this reason treatment with 
this drug leads not only to the accumulation of dihydroceramide but also of 
sphinganine (Sa), which is a sphingolipid catabolism byproduct with cytotoxic 
properties. Cabot and co-workers recently proposed a balanced effect in cell fate 
regulation for the pro-death Sa and the pro-survival Sa-1-P, that is perturbed after 
4-HPR treatment. Therefore they suggested that the 4-HPR cytotoxic effect is due 
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to the increased ratio between Sa and Sa1P [100]. These evidences suggest that 
the reduction of HGC-27 cells viability that we observed by 4-HPR treatment can 
be induced by the accumulation of sphingoid bases exacerbated  in a time and 
dose dependent manner. 
A further confirmation that dihydroceramide is involved in autophagy activation in 
HGC-27 cells resulted from the observation that stimuli or molecule, other than 4-
HPR, known to induce dihydroceramide accumulation such as hypoxia and jaspine 
B [228, 229] were similarly able to induce autophagy. We detected autophagy 
increase after real hypoxia or jaspine B (Fig. 5 panel A) within 24 hours of 
treatment. Moreover this dihydroceramide action is not only prerogative of HGC-27 
but it was also observed in breast tumoral cells treated with the metabolic inhibitor 
XM462 (Fig. 5 panel B). 
 
When we treated HGC-27 cells with the metabolic inhibitor  XM462 we observed 
that the dihydroceramide, accumulated in 4 hours, started to decline after 8 hours 
and returned back to basal level within 24 hours. Its clearance involved the 
metabolism  in more complex sphingolipids, such as dihydrosphingomyelines first, 
followed by dihydrocerebrosides and the catabolism with the release of 
dihydrosphinganine. Dihydrosphingomyelines accumulation peaked already at 8 
hours, whereas dihydro lactosyl- and dihydro glucosyl ceramides peaked at 16 
hours after treatment. Catabolism by products such as dihydrosphingosine peaked 
at  24 hours after treatment (Fig. 7). 
To confirm the direct effect of dihydroceramide on autophagy, we used a non 
metabolizable dihydroceramide analogue, d2-C8-dhCER, bearing the substitution 
of two hydrogen with two deuterium atoms, that accumulates within the cell after 
treatment. Western blotting analysis on HGC-27 treated with low concentration (2.5 
µM) of d2-C8-dhCER revealed that the analogue intracellular accumulation is able 
to induce LC3-II increase after 24 hours treatment (Fig. 5 panel A) with no sign of 
viability reduction (data not shown). 
 
Autophagy is an essential mechanism for cell survival during stress. In nutrient 
starved MEF cells autophagy is activated within minutes [238]. Kuma et al. 
demonstrated that new born mice rapidly activate autophagy in several tissues in 
response to neonatal starvation [181]. Moreover autophagy is activated in vivo and 
in vitro under hypoxic conditions as a critical adaptive mechanism to maintain 
homeostasis, leading to cell survival [183, 239]. Thus under stress condition, 
autophagy can rescue survival impairing unnecessary cell effort such as 
proliferation. Potentially dangerous stimuli such as DNA damage, hypoxia, nutrient 
starvation, or ER stress, trigger a signal cascade that, acting on check points that 
are present in particular phases of the cell cycle, addresses cell to temporary 
growth arrest. Autophagy is tightly connected with cell cycle arrest, and their 
cooperation seems part of a survival strategy that maintains cell viability while cell 
proliferation in not desirable; in addiction, cell cycle arrest and autophagy share 
common upstream signal transducer, such as mTOR inhibition. Recently Kraveka 
et al. reported human neuroblastoma cells accumulate in G0 phase after 48 hours 
transient silencing of DEGS-1 and that was associated with reduction in cell 
viability [9], moreover the up-regulation of DEGS-1 gene expression was reported 
to  up-regulate cyclin D1, thus triggering the progression from G1 to S phase.  
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Our data suggest that dihydroceramide, accumulating either in response to the 
nutrient stress mimicker resveratrol or to the sphingolipid metabolism inhibitor 
XM462, plays a role as a signalling inducer both in the regulation of cell cycle and 
autophagy, orchestrating the survival response to stressor stimuli. HGC-27 cells 
treated with XM462 delayed their progression along cycle, transiently arresting in 
G0/G1 phase, and this effect was observed since 8 hours after treatment, 
immediately after dihydroceramide accumulation. Such an effect is really peculiar 
in that we did not observed a cell cycle block that may lead to cell death, but a 
delayed ability to overcome the G0/S check point. Such a delay may actively 
enhance cell resistance since cells are known to increase their sensitivity to stress 
during the S phase. The XM462 effect on cell cycle progression, detected both by 
cell cycle analysis and protein quantification of cyclin D1 and E, was also limited at 
the gap between 4 and 24 hours, which represents the same time frame of 
dihydroceramide increase. 
Several stresses can be sensed by ER, where the activation of the UPR can 
provide cells with the opportunity to adapt to stress and survive or to commit to 
programmed cell death. Treatment of HGC-27 with fluorescent labelled short chain 
analogues of dihydroceramide and ceramide (NBD-C6- dhCer or Cer)  in co-
treatment with specific ER tracker, reveals that the dihydroceramide analogue co-
localize with ER for a longer time than the ceramide analogue (Fig. 9, panel A). 
Dihydroceramide may have a role in ER membrane composition. DEGS-1 is in fact 
an ER membrane enzyme and its activity is orientated toward the cytosolic face of 
the ER [45]. In addiction dihydroceramide shows a reduced  affinity to the carrier 
CERT than ceramide, resulting in a slow transportation from ER to Golgi [108]. 
Dihydroceramide intracellular accumulation is rapidly (within 2 hours from peaking) 
felt by ER sensors that initiate the UPR, as demonstrated by spliced XBP-1 
increase in cells treated with XM462, resveratrol and the deuterated 
dihydroceramide (Fig. 9, panel B). The UPR is a potent autophagy inducer. The 
three signaling branches of this response, PERK which phoshorylates eIF2α, IRE1 
causing XBP-1 splicing, and ATF6 trancriptional activation, activate autophagy. 
Therefore we demonstrated that tunicamycin, a known ER stress inducer, is able to 
induce autophagy similarly to XM462, resveratrol and deuterated dihydroceramide 
(Fig. 8, panel C). In addiction during ER stress, the translation inhibition of cyclin 
D1 causes cell cycle arrest in G1 phase, giving cells the opportunity to re-establish 
cellular homeostasis [146].This evidence fits with our results on the cell cycle delay 
induced by dihydroceramide accumulation.  
 
Several authors reported that the balance of saturated/unsaturated lipids affect 
biological membrane properties. Saturated, but not unsaturated, fatty acids 
accumulation within cells specifically slowed ER-to-Golgi protein trafficking, 
induceing protein overload inside the ER compartment, with consequent ER stress 
and UPR [240, 241]. Hence, the enrichment of ER membrane in dihydroceramide 
could decrease its protein permeability. Another demonstration of the effect of 
dihydrosphingolipids enrichment in membranes was reported by Stiban et al. in 
mitochondria. They proposed that the increase of saturated/unsaturated 
sphingolipid ratio in the mitochondrial membrane uploaded with dihydroceramide, 
modify its biophysical properties, inhibiting the channels formation [10]. They 
demonstrated that ceramide, biosynthesized onto ER membranes, can move to 
mitochondria and that sufficient translocated amounts result in the permeabilization 
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of the outer mitochondrial membrane to proteins [242]. Moreover, Vieira et al. 
showed that dihydrosphingomyelin enriched membranes exhibit lower penetrability 
to viruses materials [243].  
We speculate that the disruption of saturated/unsaturated sphingolipid ratio can 
affect the permeability of ER membrane and that dihydroceramide accumulation 
could reduce the ER-to-Golgi protein transport impairing vesicles formation and 
thus inducing UPR. 
 
Taken all together these data design a possible picture of the different events 
following stimuli inducing dihydroceramide accumulation (Fig. 10). Different mild 
stimuli such as hypoxia, nutrient starvation, or different molecules such as 
resveratrol, XM462, jaspin B, would trigger dihydroceramide accumulation acting, 
directly or indirectly, on DEGS-1 activity. XM462 treatment leads to a rapid 
dihydroceramide accumulation, within 4 hours after treatment (Fig. 6), possibly at 
the ER (Fig. 9). This accumulation induces an unfolded protein response 6 hours 
after treatment, that in turn induces autophagy and reduces the proliferation rate as 
a survival strategy. When  dihydroceramide amount inside ER starts to be cleared, 
due to its metabolism in complex sphingolipids, cell can proceed the cell cycle (Fig. 
6) and autophagy is reduced to baseline level (48 hours after treatment, data not 
shown) 
 
 
 
 
 
Fig. 10 Events following the stimuli inducing dihydroceramide accumulation. 
Different stimuli induce DEGS-1 inhibition and dhCER accumulation within ER. Cell 
respond to ER stress with the UPR activation that is followed by autophagy 
induction and cell cycle arrest. 
 
 
We demonstrated that resveratrol is an inducer of dihydroceramide desaturase 
activity inhibition. Dihydroceramide accumulation, in response to resveratrol or 
HPR or jaspine B or to specific pharmacological enzyme inhibitor or 
dihydroceramide analogues treatment, mediate UPR activation, autophagy 
induction and cell cycle arrest and as a pattern of pro-survival response to stress. 
This may be the very first cell response to stress. According to cell specific setting 
and to the transient or prolonged nature of stress, this response may be overcome 
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by cell demise. Our gastric cell model is deficient for p53, which acts as a 
proliferation cycling gate keeper and it was reported as autophagic repressor [231, 
244]. This is in agreement with a baseline autophagic activity in these cells and a 
high basal expression of LC3. Such deficiency may also cause the absence of 
ceramide induction that we and others previously obtained in response to 
resveratrol in a variety of cancer cells. We hypothesize that ceramide and 
apoptosis response is secondary to the cell cycle arrest, possibly via p53 induced 
cascade. In this view, the balance between dihydroceramides and ceramides can 
be important for cell to decide between survival or death. Finally, the growing 
evidences showing that dihydroceramides are signalling molecules advices to the 
need of taking with caution some of the roles previously attributed to ceramides, 
specially if the de novo pathway is involved. 
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5. CONCLUSIONS  
Classically dihydroceramide was thought as an inactive precursor of the bioactive 
ceramide [101]. Only recently some groups proposed a biological activity of 
dihydroceramide [8, 9, 100, 104].  
The results from my doctorate project first demonstrated that dihydroceramide 
accumulation is the first step of a well orchestrated cell survival strategy that 
involves: ER stress with the following induction of UPR, the modulation of cell cycle 
progression and the activation of a pro-survival autophagy.  
We first demonstrated that resveratrol, a polyphenol known for its anti-tumoral and 
antioxidant properties, induces autophagy in the human gastric cancer cell line 
HGC-27, without affecting cell viability. Next we demonstrated that resveratrol-
mediated autophagy is downstream of dihydroceramide, but not ceramide, 
signaling. We proved that resveratrol induces dihydroceramide accumulation 
through the inhibition of DEGS-1 activity, which results comparable with that 
observed treating cells with a DEGS-1 specific inhibitor. This is the first time in 
which resveratrol is described as a DEGS-1 inhibitor. Moreover, we demonstrated 
that dihydroceramide-mediated autophagy is independent from the type of the 
stimulus used for its accumulation (hypoxia, resveratrol, specific inhibitor of DEGS-
1, deuterated dihydroceramide, fenretinide or jaspine B), or from the cell model in 
which it occurs. 
We also described the dihydroceramide action on the modulation of cell cycle. 
Other groups reported that cell cycle is arrested in G0/G1 phase after DEGS-1 
activity inhibition, and that cells are then committed to cell death. Here we 
demonstrated that dihydroceramide accumulation in HGC-27 cells induces a 
temporary cell cycle arrest in G0/G1 phase, that is overcame once 
dihydroceramide is metabolized and that it is associated with autophagy induction 
and cell survival. 
Finally we demonstrated that dihydroceramide accumulation into the ER, obtained 
either via DEGS-1 inhibition or via a metabolic inactive dihydroceramide analogue, 
provokes ER stress and triggers unfolded protein response, as shown by the 
splicing of XBP-1. 
Taken all together the data here reported described dihydroceramide as a 
molecule implicated in the triggering of a pro-survival response. Its accumulation 
induces ER stress and UPR, followed by the parallel delay of cell cycle progression 
and the activation of autophagy. Thus the dihydroceramide accumulation at the ER 
may result in a strategy to guarantee the cell-survival under stressor conditions.  
Our data open a new perspective on the signaling role of sphingolipid metabolites 
which may be exploited in pharmacological approaches requiring cell proliferation 
and survival control. 
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